



(51) International Patent Classification:

A61K 39/12 (2006.01)

(21) International Application Number:

PCT/IB2017/055100

(22) International Filing Date:

24 August 2017 (24.08.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201621029037 26 August 2016 (26.08.2016) IN

(71) Applicants: **SERUM INSTITUTE OF INDIA PRIVATE LIMITED** [IN/IN]; 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra, 411 028 (IN). **THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)** [US/US]; The government of the United States of America, as Represented by the Secretary, Department of Health and Human Services, of National Institutes of Health Office of Technology Transfer, Bethesda, Maryland, 20892-7660 (US).

(72) Inventors: **DHERE, Rajeev Mhalasakant**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **PISAL, Sambhaji Shankar**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **ZADE, Jagdish Kamalaji**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **SABALE, Rajendra Narayan**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **KADAM, Ravindra Bapurao**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra. 411 028 (IN).

**KAMBLE, Abhijeet Sanjeev**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **JIANG, Baoming**; The Government of United States of America, as represented by the Secretary, Department of Health and Human Services, of National Institutes of health Office of Technology Transfer, Bethesda, Maryland 20892-7660 (US). **GLASS, Roger**; The Government of United States of America, as represented by the Secretary, Department of Health and Human Services, of National Institutes of health Office of Technology Transfer, Bethesda, Maryland 20892-7660 (US).

(74) Agent: **WILSON, Neeti** et al.; B-41, Nizamuddin East, New Delhi 110013 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MULTIVALENT VACCINE COMPOSITION

(57) Abstract: The present invention relates to stable, immunogenic combination vaccine(s) comprising a mixture of antigens for prevention and prophylaxis of infections caused by Rotavirus, Poliomyelitis virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium letani, Bordetella pertussis and Hepatitis B virus. The invention particularly provides a multivalent combination vaccine comprising of i) significantly dose reduced Salk IPV or Sabin IPV (IPV) antigens prepared by utilizing improved methods of formaldehyde inactivation and alum hydroxide adsorption resulting in maximum recovery of D-antigen and ii) Injectable heat inactivated Rotavirus antigen(s) obtained from Rotavirus (CDC-9) strains that provides a broad cross-protective immunity among human rotavirus strains, iii) Hib PRP -carrier protein conjugate having improved stability and immunogenicity wherein said Hib PRP -carrier protein conjugate is initially prepared by using novel conjugation process and subsequently blended at low temperature in presence of a stabilizer for minimizing free PRP release iv) whole cell pertussis antigen with improved immunogenicity and stability obtained by addition of whole cell pertussis antigen at a later stage in a blend thereby minimizing hydrolysis based degradation v) Homogenous fractions of Diphtheria toxoid and Tetanus toxoid obtained by removal of undesirable aggregates by using Gel Permeation chromatography. The process of making such stable and immunogenic vaccine compositions by i) individually adsorbing dose reduced IPV. IRV antigens on alum hydroxide and keeping other antigen(s) unadsorbed or adsorbed on Alum Phosphate, Alum hydroxide, on a combination of Alum hydroxide and Alum phosphate and ii) using a particular order of addition of antigens during blending is also disclosed.



WO 2018/037365 A1

**Published:**

— *with international search report (Art. 21(3))*

**MULTIVALENT VACCINE COMPOSITION****Field of the Invention:**

5 The present invention relates to stable combination vaccine(s) comprising a mixture of antigens for prevention and prophylaxis of infections caused by Rotavirus, poliomyelitis virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis (whole cell) and Hepatitis B virus. The invention in particular relates to a stable multivalent combination vaccine comprising of significantly dose reduced Salk IPV or Sabin  
10 IPV (IPV) antigens and injectable heat inactivated Rotavirus antigen(s) obtained from Rotavirus (CDC-9) strains.

**Background of the invention:**

15 The poliovirus invades the nervous system and can cause irreversible paralysis in a matter of hours. Three types of poliovirus exist globally i.e. Type 1, Type 2, & Type 3.

The prevalence of polio virus has largely been decreased by the use of Oral Polio Vaccine (OPV), based on live-attenuated Sabin polio strains. However, OPV has limitations for the  
20 post-eradication era. OPV contains circulating vaccine-derived polioviruses (cVDPVs) which are transmissible and can become neurovirulent (similar to wild polioviruses) resulting in vaccine associated paralytic poliomyelitis. Such strains can potentially re-seed the world with polioviruses and negate the eradication accomplishments. To prevent the emergence of circulating vaccine-derived polioviruses (cVDPVs), WHO's Strategic  
25 Advisory Group of Experts (SAGE) has recommended atleast one dose of IPV along with Oral Polio Vaccine (OPV) in countries currently using OPV. (Ref: World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 – conclusions and recommendations. Wkly Epidemiol Rec 2013; 88:1-16; PMID:23311010).

30

Presently, IPV is made using wild polio strain i.e. Salk strain and the newer sabin strains which is made from the same attenuated Sabin strains as those used in the live attenuated OPV. The approved standard dose of polio vaccines delivered by intramuscular (IM) or deep subcutaneous (SC) injection contains D antigens as 40 Units of inactivated poliovirus type 1

(Mahoney), 8 units of inactivated poliovirus type 2 (MEF-I) and 32 units of inactivated poliovirus type 3 (Saukett) (e.g. Infanrix-IPV™). But IPV has high production costs as compared to OPV, mainly due to requirements for more virus per dose; additional downstream processing (i.e. concentration, purification and inactivation), and the related QC-testing; loss of antigen or poor recovery in downstream; and containment.

The production costs of IPV is currently estimated to be about 20-fold more expensive than OPV. The future global demand for IPV following eradication of polioviruses could increase from the current level of 80 million doses to 450 million doses per year. Therefore to reduce the final cost of IPV, efforts are undergoing to reduce the quantity of antigenic components i.e. to produce dose reduced IPV formulations.

Globally, Rotavirus is the leading cause of severe acute diarrhea and vaccine is found a promising solution to reduce the disease burden. It has been estimated that the number of rotavirus deaths in the world declined from 528 000 to 215 000 during thirteen years from 2000 to 2013, since rotavirus vaccine had been introduced in >60 countries . Out of that, an estimated 47 100 (22%) rotavirus deaths occurred in India in 2013. India, Nigeria, Pakistan, and Democratic Republic of Congo, these four countries accounted for approximately half (49%) of all estimated rotavirus deaths in 2013 .

In recent studies carried worldwide, it is observed that 4 serotypes of rotavirus i.e. G1, G2, G3 and G4 represents over 88% of the strains analyzed globally. The G1 serotype of rotavirus A is one of the most common forms of the virus which cause the disease worldwide, whereas serotype G9 viruses associated have been emerging since the late 1990s and now represent approximately 4% of global isolates. Vaccination against rotavirus-mediated disease is one strategy for addressing this significant health problem. The two currently licensed oral rotavirus vaccines, RotaTaq and Rotarix, which are very effective in reducing cases of severe diarrhea among children in developed and middle income countries, are much less efficacious (~50%) in low income countries of Africa and Asia. [Refer Tate JE et al. "Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. *Pediatr Infect Dis J* 2011; 30:S30-4; and Yen C et al. "Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador". *Pediatr Infect Dis J* 2011; 30:S6-10]. In addition, the two current rotavirus vaccines have been associated with a risk of

intussusception among vaccinated infants. [Refer Patel MM et al. "Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. *N Engl J Med* 2011; 364:2283-92 and Buttery JP et al. "PAEDS/APSU Study Group. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia". *Vaccine* 2011; 29:3061-6].

One of the candidate Rotavirus vaccine of Bharat Biotech International is based on a 116E rotavirus strain, G9P[11] which is a naturally occurring reassortant containing one bovine rotavirus gene P[11] and ten human rotavirus genes. The protection offered by this vaccine during the first 2 years of life is against the array of circulating genotypes including G1P[8], G2P[4], G12P[6], G12P[8] and G9P[4]. Thus it fails to provide cross protection for other strains like G3, G4, G5, G6, G8, G10, G11, G13 and G14. Also the efficacy of 116E based vaccine in the first 2 years of life has been modest (48 to 55%) as it is for other licensed vaccines. [Refer Nita Bhandari et al. "Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life"; *Vaccine*. 2014 Aug 11;32 Suppl 1:A110-6]. Also, preclinical testing of several other intramuscularly administered IRV candidates that were based on G1, G3 or G6 have only shown partial protection.

Also inactivation of Rotavirus with  $\beta$ -propiolactone (BPL), an agent commonly used for the inactivation of many viruses, has been shown to cause severe damage to the integrity and biochemical composition of rotavirus particles. In addition, BPL-treated rotavirus showed reduced viral hemagglutinating activity and intramuscular injection with this material in mice evoked less neutralizing antibody than immunization with live virus. [Refer Offit PA et al "Noninfectious rotavirus (strain RRV) induces an immune response in mice which protects against rotavirus challenge". *J Clin Microbiol* 1989; 27:885-8].

In many parts of the world, immunization with IPV has already replaced OPV so that in a few years, rotavirus vaccine will be the only vaccine administered orally adding to delivery costs. Several operational and logistic considerations thus favor an IRV for use in both developing and industrialized countries.

The appearance of dimers in D/T, seems to be a consequence of the detoxification process by formalin. The existence of dimers can affect the efficiency of the conjugation process – presumably through steric hindrance at the protein surface – leading to a loss of activity, and

it is considered desirable that the level of monomers should not drop below 80%. Previously, it has been reported that T with atleast 60% monomer can be obtained by using HIC followed by Ion exchange; T with 73% monomer content can be obtained by using only HIC Phenyl sepharose, T with 55 % monomer content can be obtained by using only Ammonium sulphate. Therefore an alternative single step method is needed to obtain D/T having atleast 80% monomer.

Combination vaccines comprises of two or more vaccines that could be given individually and put them into a single composition. Vaccinee gets the same protection as they do from individual vaccines given separately, but with fewer shots. A combination vaccine thus provides immunogenicity against large number of diseases and is always advantageous over the monovalent vaccines as the compliance is increased by reducing the number of separate vaccinations.

A heptavalent combination vaccine is being developed by Bharat Biotech International that consists of D, T, Acellular pertussis, Sabin IPV (type 1: 40 DU, type 2:8 DU, type 3 :32DU), Single strain inactivated Rotavirus (G9 strain i.e. 116E strain), a conjugate Haemophilus influenza type b PRP conjugate to TT and a Recombinant Hepatitis B vaccine. As discussed earlier, such Heptavalent combination vaccine comprising of 116E based vaccine would fail to provide cross protection for other strains like G3, G4, G5, G6, G8, G10, G11, G13 and G14. Further the efficacy of said IRV component of combination vaccine in the first 2 years of life will be modest (48 to 55%) as it is for other licensed vaccines.

Another combination vaccine, Hexyon® (also called Hexacima® and Hexaxim®) from Sanofi Pasteur, contains aP. This vaccine is likely to be targeted for private markets in Europe and worldwide. Another hexavalent combination vaccine with aP antigen is currently in Phase III clinical studies, developed jointly by Merck and Sanofi Pasteur.

Currently, GSK's Infanrix Hexa® is the only globally marketed hexavalent pediatric combination vaccine containing IPV. This vaccine contains an acellular pertussis (aP) component and is presented in a syringe-plus-lyophilized vial format because of instability of the Hib component. The major barriers for use of Infanrix Hexa® (GSK), in a developing- country setting are the price of the vaccine product, the requirement for reconstitution of a lyophilized form, and concerns regarding effectiveness of an aP vaccine

in the developing world. From a cost perspective, aP antigens have historically exceeded the cost of wP antigens by a factor of ten to more than 30 due to manufacturing differences and royalty costs. Thus, use of whole cell pertussis (wP) in multivalent combination vaccines intended for developing countries has become important both because of cost and emerging concerns about the long-term effectiveness of aP vaccines, especially in developing-country settings.

Several multivalent combination vaccines with wP and IPV are under development. However IPV antigens are not compatible with the common vaccine preservative thimerosal, a mercury-containing compound with antibacterial activity, which causes the polio capsid to lose its antigenicity. Thimerosal is used by many vaccine manufacturers in the inactivation of live *B. pertussis* organisms to make wP vaccine bulks, which is carried through into the final product, but also causes loss of antigenicity of IPV, and therefore IPV may need to be presented in a separate vial from thiomersal-containing wP to retain its potency over time.

GSK's whole-cell combination vaccine (DTwP-IPV-HBV//Hib) is reported to be in several early clinical trials. However the polio immunogenicity of this product was not as good as a comparator vaccine and it was found that the IPV dose would minimally need to be the same as the current standard IPV dose vaccine or may need to be increased.

Reduced-dose efficacious vaccine formulations which provide protection against infection using a lower dose of IPV antigen are desirable in situations where the supply of conventional vaccine is insufficient to meet global needs or where the cost of manufacture of the conventional vaccine prevents the vaccine being sold at a price which is affordable for developing countries. Also the exposure to lower dose of IPV; compared to the existing marketed formulations could be safer. A multivalent combination vaccine could simplify complex pediatric routine immunization schedules, improve compliance, and reduce delivery costs. However, IPV-containing multivalent vaccines have been a technical challenge for vaccine manufacturers since work began in the early 1990s to combine pediatric vaccines.

Instability of Hib antigen in the presence of aluminum adjuvant, more specifically aluminum hydroxide is a major technical issue. Thus the technical challenge that a manufacturer would need to resolve would be the avoidance of different aluminum adjuvants, if the vaccine bulks

going into the combination already had been based on different aluminum chemistries. Thus the sequence of addition of antigen becomes an important factor, as mixing of incompatible antigens or adjuvants may lead to undesired physical appearances for the final product (such as extra precipitates and difficulty in re-suspension) further resulting in unacceptance of the final combination vaccine product [Refer Malecker et al 1996, "Factors affecting the ability of experimental vaccines to protect guinea pigs against lethal challenge with Diphtheria Toxin"; presented at WHO/IABS/NIBSC International meeting on the control and standardization of Acellular pertussis Vaccines, UK, Sep 26-27 1996].

The currently known and available combination vaccines may not contain appropriate formulations of appropriate antigens in appropriate immunogenic forms for achieving desired levels of efficacy and immunogenicity in the susceptible human population, for a number of diseases in one shot. Most importantly, no multivalent combinations with dose reduced IPV (IPV), broadly cross-protective IRV and whole cell pertussis (wP) are commercially available. Given the above discussed scenario with respect to combination vaccines, there remains a distinct need for affordable all liquid multivalent combination vaccine(s) suitable for developing world providing equivalent or improved seroprotection for individual antigens devoid of antigenic interference.

#### Summary of Invention:

The present invention relates to stable, immunogenic combination vaccine(s) comprising a mixture of antigens for prevention and prophylaxis of infections caused by Rotavirus, Poliomyelitis virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and Hepatitis B virus. The invention particularly provides a multivalent combination vaccine comprising of i) significantly dose reduced Salk IPV or Sabin IPV (IPV) antigens prepared by utilizing improved methods of formaldehyde inactivation and alum hydroxide adsorption resulting in maximum recovery of D-antigen and ii) Injectable heat inactivated Rotavirus antigen(s) obtained from Rotavirus (CDC-9) strains that provides a broad cross-protective immunity among human rotavirus strains, iii) Hib PRP -carrier protein conjugate having improved stability and immunogenicity wherein said Hib PRP -carrier protein conjugate is initially prepared by using novel conjugation process and subsequently blended at low temperature in presence of a stabilizer for minimizing free PRP release iv) whole cell pertussis antigen with improved

immunogenicity and stability obtained by addition of whole cell pertussis antigen at a later stage in a blend thereby minimizing hydrolysis based degradation v) Homogenous fractions of Diphtheria toxoid and Tetanus toxoid obtained by removal of undesirable aggregates by using Gel Permeation chromatography .The process of making such stable and immunogenic vaccine compositions by i) individually adsorbing dose reduced IPV, IRV antigens on alum hydroxide and keeping other antigen(s) either unadsorbed or adsorbed on Alum Phosphate or Alum hydroxide , or a combination of both and ii) using a particular order of addition of antigens during blending is also disclosed. Further, present invention provides affordable combination vaccine(s) suitable for developing world providing equivalent or improved seroprotection for individual antigens devoid of antigenic interference.

#### Figures:

Figure 1: Diphtheria Toxoid Purification - Chromatogram of Gel Filtration Chromatography Sephacryl S-300 HR, Column XK 26/70.

#### Detailed Description:

The present invention relates to multivalent combination vaccine(s) comprising of (i) dose reduced inactivated polio virus vaccine selected from sabin or salk strains; (ii) injectable heat inactivated rotavirus CDC-9 strains; and (iii) optionally, one or more antigens selected from D, T, wP HBsAg, Hib PRP-Carrier protein conjugate, Neisseria meningitidis A antigen(s), Neisseria meningitidis C antigen(s), Neisseria meningitidis W-135 antigen(s), Neisseria meningitidis Y antigen(s), Neisseria meningitidis X antigen(s), Streptococcus Pneumoniae antigen(s), Neisseria meningitidis B bleb or purified antigen(s), Staphylococcus aureus antigen(s), Anthrax, BCG, Hepatitis A antigen(s), Hepatitis B antigen, Human papilloma virus, Salmonella Typhi antigen(s) , acellular pertussis , modified adenylate cyclase , Malaria Antigen (RTS,S), Measles, Mumps, Rubella, Dengue, Zika, Ebola, Chikungunya, Japanese encephalitis, Diarrheal antigens, etc.

#### 30 **Components of the Combination Vaccine composition:**

- Inactivated Polio Virus

Polio (Poliomyelitis) is a highly infectious virus. The poliovirus invades the nervous system and can cause irreversible paralysis in a matter of hours. Three types of poliovirus exist

globally i.e. Type 1, Type 2, & Type 3.

First embodiment of the present invention comprises of improved methods of Polio virus (salk or sabin strains) inactivation by formaldehyde in presence of TRIS buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said IPV on aluminum hydroxide provides significantly dose reduced IPV compositions. The instant invention provides an improved process of formalin inactivation and aluminum hydroxide adsorption, wherein the D -Antigen recovery post-inactivation is in the range of 50–80% and percent adsorption of aluminum hydroxide is in the range of 70–99 %.

In one of the aspects of the first embodiment, CCL81-VERO (Monkey kidney) cell were used as host cells for the growing of polio virus i.e. sabin and salk strains. After infection of host cells with desired strain of polio virus and incubation of 72 hours, the medium containing the virus and cell debris was pooled and collected in a single container.

In second aspect of the first embodiment, the harvest was subjected to series of filtration (6  $\mu$  and 0.45  $\mu$  assembly); and filtrate was collected in a glass container. The filtrate was subjected to tangential flow filtration with 100kDa cassette; diafiltered using phosphate buffer and purified using anion exchange chromatography.

In third aspect of the first embodiment, the purified virus pool was further subjected to buffer exchange from Phosphate buffer to Tris buffer (30 to 50mM, pH: 7 – 7.5) with TFF system (100 kDa, 0.1 m<sup>2</sup>) followed by addition of M-199 and 0.1 – 1.0 % glycine.

In fourth aspect of the first embodiment purified virus pool in Tris buffer was subjected to inactivation by 0.01 – 1.0 % formalin with continuous stirring of virus bulk and incubated at ambient temperature for 13 days, with intermediate filtration on day 7. Further, the inactivated bulk was subjected to final filtration and later stored at 2-8 °C.

In fifth aspect of the first embodiment, final purified bulk was subjected to adsorption on Al(OH)<sub>3</sub>, wherein the final alum (Al<sup>3+</sup>) concentration is between 0.1 – 1.5 mg/dose, M-199+0.5% glycine was used to make up the volume and pH was adjusted to 6 – 7 using 1N HCl/NaOH, further subjected to overnight stirring at 2 – 8 °C.

The present inventors have surprisingly observed that D-antigen loss, post-formaldehyde inactivation was due to presence of phosphate buffer that unexpectedly causes undesirable aggregation of polio viruses. The instant invention provides an improved process of formaldehyde inactivation in presence of TRIS buffer thereby ensuring minimal epitopic modifications and subsequently minimizing D-antigen loss.

◆ Inactivated Rotavirus:

Rotaviruses are the most common cause of severe diarrhoeal disease in young children throughout the world. Oral, live, attenuated rotavirus vaccines are available internationally; and are considered safe and effective in preventing gastrointestinal disease.

Second embodiment of the present invention comprises of preparation, purification and formulation of the rotavirus. The said process for preparation of Injectable heat Inactivated Rotavirus antigens having novel strain i.e. CDC-9 utilizes thermal inactivation and adsorption on aluminum hydroxide adjuvant.

In first aspect of the second embodiment, Rota virus was cultured using Vero cells (CCL-81) as host cells and the harvest was clarified using 30  $\mu$  and 2  $\mu$  filter assembly to remove cell debris.

In second aspect of the second embodiment, the clarified harvest was treated with Benzonase (2000–10000 units per liter) with incubation at 37°C for 4 hours and continuous stirring. More particularly the concentration of benzonase used was 5000 units per liter.

In third aspect of the second embodiment, Benzonase treated bulk was further 10X concentrated and 4X diafiltered using 'HBSS (Hanks Balanced Salt Solution) + 10% sorbitol' with 100 kDa cassettes.

In fourth aspect of the second embodiment, the diafiltered bulk can be optionally dialysed using a dilution buffer and further purified using affinity chromatography, preferably cellulose sulfate as a column chromatography resin.

In the fifth aspect of the second embodiment, an improved method of thermal inactivation of rotavirus was used. The method is rapid, simple, and can maintain the integrity and thereby

preserve the antigenicity of Rotavirus particles. The temperature used for thermal inactivation was in range between 60°C to 70°C; and incubation time was in the range of about 10 minutes-24 hours, inclusive. Preferably the incubation time was in the range of about 30 minutes-10 hours. More preferably, inactivation of purified CDC-9 was done using heat at 60 ° C for 5 hrs with one change of container after two hours. The inactivated CDC-9 bulk was stored at -80°C until further use.

In sixth aspect of the second embodiment, adsorption of Inactivated Rotavirus antigen was done on Aluminium hydroxide, wherein the final Aluminum ( $Al^{+++}$ ) concentration was between 0.2 mg/dose to 0.8 mg/dose.

• *Haemophilus influenzae* b PRP – Protein Conjugate :

*Haemophilus influenzae* type b is a Gram-negative bacterium that causes meningitis and acute respiratory infections, mainly in children. The outermost structure of *H. influenzae* type b is composed of polyribosyl-ribitol-phosphate (PRP), a polysaccharide that is responsible for virulence and immunity. PRP is a hapten which is considered as poor immunogenic in nature hence PRP is linked covalently with a carrier protein to make highly immunogenic Hib antigen. This process changes the polysaccharide from a T-independent to a T-dependent antigen and greatly improves immunogenicity, particularly in young children.

Third embodiment of the present invention comprises of preparation of Hib PRP-protein conjugate. It may be noted that the carrier proteins used for the conjugation of the Hib antigen may be selected from group comprising of CRM<sub>197</sub> (Cross Reactive Material 197, a genetically detoxified form of diphtheria toxoid), Diphtheria toxoid, *Neisseria meningitidis* outer membrane complex, fragment C of tetanus toxoid, pertussis toxoid, protein D of *H. influenzae*, *E. coli* LT, *E. coli* ST, and exotoxin A from *Pseudomonas aeruginosa*, outer membrane complex c (OMPC), porins, transferrin binding proteins, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), pneumococcal PhtD, pneumococcal surface proteins BVH-3 and BVH-11 , protective antigen (PA) of *Bacillus anthracis* and detoxified edema factor (EF) and lethal factor (LF) of *Bacillus anthracis*, ovalbumin, keyhole limpet hemocyanin (KLH), human serum albumin, bovine serum albumin (BSA) and purified protein derivative of tuberculin (PPD), synthetic peptides, heat shock proteins, pertussis proteins, cytokines, lymphokines, hormones, growth factors, artificial proteins comprising multiple human CD4+ T cell epitopes from various

pathogen-derived antigens such as N 19, iron-uptake proteins, toxin A or B from *C. difficile* and *S.agalactiae* proteins or any equivalents thereof. Preferably the carrier protein in conjugate is selected from TT or CRM<sub>197</sub>.

5 In first aspects of the third embodiment, Hib antigen is derived from the capsular polysaccharide of *Haemophilus influenzae* type b strain. To produce the PRP polysaccharide, *H. Influenzae* type-b bacteria was grown in semi synthetic media under certain conditions of temperature, agitation and optical density etc. PRP is an outer membrane bound polysaccharide, gets released into the medium during the fermentation  
10 under agitation condition. Fermented biomass separated broth contains crude PRP, which was again purified by precipitation using a detergent N, N, N-trimethyl-1-hexadecanaminium bromide, followed by ethanol gradient precipitation and filtration. Final purified PRP polysaccharide was tested for meeting the specifications like endotoxin, nucleic acid and protein as per the WHO, BP, EP, IP etc.

15

In second aspect of the third embodiment, polysaccharide – protein conjugate was prepared by coupling of polysaccharide (PRP) with a carrier protein. Hib PRP was conjugated to carrier protein using conjugation process comprising of steps including depolymerization of PRP using alkaline buffer to achieve size reduced PRP; treatment with cyanylation agent  
20 like CDAP (1-cyano-4-dimethylamino pyridinium tetrafluoroborate) to form a cyanate ester; coupling of activated cyanylated polysaccharide to amino group of carrier protein; purification of final conjugate using ultrafiltration.

More preferably, the optimal input ratio of reactants *i.e.* PRP, CDAP and CRM<sub>197</sub> was  
25 selected at 1:1.5:1 ratio for conjugation reaction. During conjugation, purified PRP polysaccharide was depolymerized using an alkaline buffer (0.4M Carb-Bicarbonate buffer, pH 10.5 ±0.1) to achieve size reduced PRP. Size reduced PRP was treated for cyanylation using CDAP (1-cyano-4-dimethylamino pyridinium tetrafluoroborate) chemistry to form a cyanate ester. The activated cyanylated polysaccharide was coupled directly with amino  
30 group on the carrier protein CRM<sub>197</sub>. The degree of conversion of Hib conjugate was confirmed by the offline testing using HPLC. The conjugation reaction was quenched by achieving the desired level of conversion of conjugate with the specification of not less than 65% conversion of Hib conjugate, and then conjugate reaction was neutralized by Glycine (2M) addition. The Hib PRP-CRM<sub>197</sub> Conjugate was further purified on ultra filtration

membrane filters (300kDa and 100kDa) to remove nonreactive reagents and byproducts. Final conjugate bulk is 0.22 µm filtered and stored at 2-8°C.

In third aspect of the third embodiment, Hib PRP is conjugated to carrier protein wherein the saccharide: protein ratio (w/w) is between 0.4 and 1; and the free PRP content in final Hib PRP – protein conjugate bulk is not more than 5%, more preferably is less than 2%.

- Diphtheria toxoid (D)

Diphtheria is an infectious disease caused by the bacterium *Corynebacterium diphtheria*, which primarily infects the throat and upper airways, and produces a toxin affecting other organs. Diphtheria toxin is an exotoxin secreted by *Corynebacterium diphtheria*, possesses antigenic properties and is toxic in nature. To reduce toxicity, the toxin is converted to the inactive toxoid by subjecting it to inactivation. The inactivation process may be selected from one or more of treatment with Heat, UV, Formalin /Formaldehyde, Acetyleneimine, etc. To increase immunogenicity, the toxoid is adsorbed to an adjuvant. The toxoid thus formed is able to induce anti toxin antibodies against *C diphtheria*. Existence of dimers can lead to adverse reactions.

In fourth embodiment of the present invention, Diphtheria toxoid was prepared.

In first aspect of the fourth embodiment, diphtheria toxin (exotoxin) was obtained from *Corynebacterium diphtheria* and detoxified using a suitable inactivating agent. The example of suitable inactivating agent includes Formaldehyde.

In second aspect of the fourth embodiment, diphtheria toxoid obtained was purified using Gel filtration chromatography with Sephacryl S-300 HR as resin with linear flow rate of 2 – 5 ml/min. The purified D thus obtained comprises of homogenous fraction devoid of undesirable aggregates (Refer Figure 1) with atleast 80 – 90 % monomeric diphtheria toxoid further used for formulation of multivalent vaccine(s). Further PLgel, Sephacryl S-200HR, Sephadex, Bio-Gel (cross linked polyacrylamide), agarose gel and/or Styragel may also be used for the purpose of purification using Gel permeation chromatography.

In third aspect of the fourth embodiment, diphtheria toxoid was adsorbed on one or more of Aluminum salt including Aluminum hydroxide and Aluminum phosphate, preferably on

Alum phosphate.

\* Tetanus toxoid (T)

Tetanus is an acute infectious disease caused by toxigenic strains of the bacterium  
5 Clostridium tetani (C. tetani), a gram-positive, spore-forming, strictly anaerobic bacterium.  
Tetanus toxin is an exotoxin secreted by Clostridium tetani, possesses antigenic properties  
and is toxic in nature. To reduce toxicity, the toxin is converted to the inactive toxoid by  
subjecting it to inactivation. The inactivation process may be selected from one or more of  
10 treatment with Heat, UV, Formalin /Formaldehyde, Acetyleneimine, etc. To increase  
immunogenicity, the toxoid is adsorbed to an adjuvant. The toxoid thus formed is able to  
induce anti toxin antibodies against Clostridium tetani. Existence of dimers can lead to  
adverse reactions.

In fifth embodiment of the present invention, Tetanus toxoid was prepared.

15

In first aspect of the fifth embodiment, Tetanus toxin was obtained from Clostridium tetani  
and detoxified using a suitable inactivating agent. The example of suitable inactivating agent  
includes Formaldehyde.

20

In second aspect of the fifth embodiment, Tetanus toxoid obtained was purified using Gel  
filtration chromatography with Sephacryl S-300 HR as resin with linear flow rate of 2 – 5  
ml/min. The purified T thus obtained was a homogenous fraction devoid of undesirable  
aggregates with atleast 80 – 90 % monomeric tetanus toxoid further used for formulation of  
multivalent vaccine. Further PLgel, Sephacryl S-200HR, Sephadex, Bio-Gel (cross-linked  
25 polyacrylamide), agarose gel and Styragel may also be used for the purpose of purification  
using Gel permeation chromatography.

30

In third aspect of the fourth embodiment, Tetanus toxoid was adsorbed on one or more of  
Aluminum salt including Aluminum hydroxide and Aluminum phosphate, preferably on  
Alum phosphate.

\* Pertussis Antigen

Pertussis (whooping cough) is caused by *Bordetella pertussis*, a small Gram-negative  
coccobacillus that infects the mucosal layers of the human respiratory tract. Two forms of

vaccine are in use, the whole-cell pertussis vaccine (wP), and the acellular pertussis vaccine (aP). Whole-cell pertussis vaccines are suspensions of the entire *B. pertussis* organism that has been inactivated, usually with formalin. Immunization with wP vaccine is relatively inexpensive and highly effective. Also, presence of wP in combination vaccines acts as an adjuvant for many other antigenic component.

Acellular pertussis (aP) vaccines contain purified components of *B. pertussis* such as inactivated pertussis toxin either alone or in combination with other *B. pertussis* components such as filamentous haemagglutinin, fimbrial antigens, pertactin, and modified adenylate cyclase. Acellular pertussis vaccine offers less adverse reaction as compared to wP vaccine.

In sixth embodiment of the present invention, the pertussis vaccine is pertussis antigen selected from one or more of whole cell pertussis or acellular pertussis.

In first aspect of the sixth embodiment, pertussis vaccine is an acellular pertussis antigen selected from one or more of filamentous haemagglutinin, fimbrial antigens, pertactin, and modified adenylate cyclase. Acellular pertussis antigens may be expressed in suitable host using recombinant DNA technology.

In second aspect of the sixth embodiment, pertussis vaccine is a whole cell pertussis comprising of *Bordetella pertussis* strains 134, 509, 25525 and 6229 in a specific ratio and subsequently inactivated by utilizing improved methods of inactivation devoid of thimerosal; hence leading to reduced reactogenicity and increased potency. Preferably, wP antigen is made from *Bordetella pertussis* strains 134, 509, 25525 and 6229 mixed in a ratio of 1:1:0.25:0.25.

In third aspect of the sixth embodiment, wP inactivation process includes heat inactivation at  $56 \pm 2^\circ\text{C}$  for 10 to 15 minutes in presence of formaldehyde; wherein wP bulk remains non-clumpy and easily homogenized thereby leading to reduced reactogenicity and giving better wP potency for a longer duration.

- Hepatitis B surface antigen (HBsAg)

Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus (HBV). Hepatitis B surface antigen (HBsAg) is a surface protein that also acts as an

immunogen in highly effective vaccines for prevention of HBV infection. HBsAg protein can be recombinantly expressed in a suitable host microorganism; or can be isolated from the blood plasma of a chronic Hepatitis B patient/carrier.

5 In seventh embodiment of the present invention, Hepatitis B surface antigen (HBsAg) was prepared.

In one of the aspect of seventh embodiment, HBsAg was expressed in Hansenula polymorpha yeast cells using recombinant DNA technology. Other yeasts such as *Saccharomyces cerevisiae* may also be used as host cell for recombinant expression of  
10 HBsAg.

In one of the aspect of seventh embodiment, Hepatitis B antigen (HBsAg) was adsorbed on one or more of Aluminum salt including Aluminum hydroxide and Aluminum phosphate, preferably on Alum phosphate.

15

#### Bivalent Combination Vaccine composition and its preparation process

In eighth embodiment of the present invention, multivalent vaccine is an all liquid bivalent combination vaccine. The bivalent combination vaccine comprises of an inactivated polio  
20 virus of Type I, II and III; and Inactivated Rota virus (IRV).

In first aspect of the eighth embodiment, Inactivated polio virus is selected from the group of Salk and Sabin strain; and the concentration of individual Type 1, Type 2, and Type 3 of Salk or Sabin strain based IPV is not more than 20 D antigen units.

25

In second aspect of the eighth embodiment, inactivated polio virus is a Salk strain and the concentration of individual Type 1, Type 2, or Type 3 of Salk strain based IPV is selected from the group of dose composition comprising of 7.5-16-10, 8-2-5, 10-2-5, 10-2-10, 10-2-12, 10-2-16, 7.5-16-10, 5-2-5 D antigen units; more particularly concentration of individual  
30 Type 1, Type 2, or Type 3 of Salk strain based IPV is selected from group of 8-2-5 and 10 – 2 – 10 D antigen units.

In third aspect of the eighth embodiment, inactivated polio virus is a Sabin strain and the concentration of individual Type 1, Type 2, and Type 3 of Sabin strain based IPV is selected

from the group of dose composition comprising of 5-16-10, 2.5-8-5, 5-8-10 D antigen units; more particularly concentration of individual Type 1, Type 2, and Type 3 of Sabin strain based IPV is 5-16-10 D antigen units.

- 5 In fourth aspect of the eighth embodiment, injectable heat inactivated rotavirus (IRV) is a Rotavirus CDC-9 or CDC-66 strain and the concentration of IRV is in the range of 5 – 50 µg/dose, more particularly the concentration of IRV is 10 µg/dose.

In fifth aspect of the eighth embodiment, bivalent composition was prepared by adsorbing  
10 IPV (Sabin/Salk strain) bulk and IRV bulk individually on one or more of Aluminum salt including Aluminum hydroxide and Aluminum phosphate, preferably on Alum hydroxide. The individual monovalent adsorbed bulks of IPV and IRV were further mixed together and kept on rocker at 2 – 8 °C for 1 – 4 hours.

15 **Hexavalent Combination Vaccine composition and its preparation process**

In ninth embodiments of the present invention, all liquid Hexavalent (DTwP-IPV-IRV-Hib) vaccine formulation was prepared as follows:

- 20 a) IPV (Sabin/Salk strain) bulk and IRV bulk were individually adsorbed on Aluminum hydroxide, followed by pH adjustment to 6.2 – 6.6.
- b) D was adsorbed on Aluminum phosphate, followed by pH adjustment to 5.5 – 6.5, addition of T and blending by agitation at room temperature for 18 – 24 hours.
- c) The solutions obtained in step a and b were mixed, followed by pH adjustment to 6.4 – 6.6 and agitation at RT for 60 minutes.
- 25 d) wP antigen and Histidine were added to the above mixture, followed by agitation for 60 minutes and left in static condition for overnight at 2 – 8 °C.
- e) Hib PRP conjugate and 2-Phenoxyethanol (2-PE) were added to the mixture obtained in step d at 2 – 8 °C, followed by pH adjustment to 6.4 – 6.6.
- 30 f) NaCl and WFI (q.s.) were added to the mixture obtained in step e, followed by agitation for 2 hours.

In tenth embodiment of the present invention, the multivalent vaccine composition is an all liquid hexavalent vaccine formulation. All liquid hexavalent vaccine formulation comprises

of Diphtheria toxoid (D); Tetanus toxoid (T); Inactivated whole cell B. pertussis antigen (wP); Inactivated polio virus salk strains of Type I, II and III; Inactivated Rota virus (IRV); and H. influenzae type b PRP-TT conjugate and other excipients like Aluminum based adjuvant (Aluminum phosphate, Aluminum hydroxide), 2-phenoxyethanol, L-Histidine and WFI.

In one of the preferred aspect of the tenth embodiment, the multivalent vaccine composition is an hexavalent vaccine composition wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1-30 Lf; wP is present in an amount in the range of 10-50 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1-30 µg; H. influenzae type b PRP-TT conjugate is in an amount in the range of 2-20 µg of PRP content; aluminum content ( $Al^{3+}$ ) is present in an amount in range of 0.4 – 1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg and WFI.

In one of the most preferred aspect of the tenth embodiment, the multivalent vaccine composition is an hexavalent vaccine composition wherein D is present in an amount 22.5 Lf; TT is present in an amount 7.5 Lf; wP is present in an amount 15 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount 10 D units, type 2 is present in an amount 2 D units, Type 3 is present in an amount 10 or 16 D units; IRV is present in an amount 10 µg; influenzae type b PRP-TT conjugate is in an amount 5 µg ; Aluminum content is present in an amount not more than 0.9 mg; 2-Phenoxyethanol is present in an amount 3.25 mg; L-Histidine is present in the amount of 1.55 mg and WFI.

In eleventh embodiments of the present invention, the multivalent vaccine composition is an all liquid hexavalent vaccine formulation. All liquid hexavalent vaccine formulation comprises of Diphtheria toxoid (D); Tetanus toxoid (T); Inactivated whole cell B. pertussis antigen (wP); Inactivated polio virus salk strains of Type I, II and III; Inactivated Rota virus (IRV); and H. influenzae type b PRP-CRM<sub>197</sub> conjugate and other excipients like Aluminum based adjuvant (Aluminum phosphate, Aluminum hydroxide), 2-phenoxyethanol, L-Histidine and WFI.

In one of the preferred aspect of the eleventh embodiment, the multivalent vaccine composition is an hexavalent vaccine composition wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1-30 Lf; wP is present in an amount in the range of 10-50 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount in the range of 1 – 20 D units, type 2 in the range of 1 – 20 D units, Type 3 in the range of 1 – 20 D units; IRV is present in an amount in the range of 1-30 µg; H. influenzae type b PRP- CRM<sub>197</sub> conjugate is in an amount in the range of 2-20 µg of PRP content; aluminum content (Al<sup>3+</sup>) is present in an amount in range of 0.4 – 1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6mg; L-Histidine is present in the range of 0.5 – 5 mg and WFI.

In one of the most preferred aspect of the eleventh embodiment, the multivalent vaccine composition is an hexavalent vaccine composition wherein D is present in an amount 22.5 Lf; T is present in an amount 7.5 Lf; wP is present in an amount 15 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount 10 D units, type 2 is present in an amount 2 D units, Type 3 is present in an amount 10 or 16 D units; IRV is present in an amount 10 µg; H influenzae type b PRP- CRM<sub>197</sub> conjugate is in an amount 10 µg; Aluminum content is present in an amount not more than 0.9 mg; 2-Phenoxyethanol is present in an amount 3.25 mg; L-Histidine is present in the range of 1.55 mg and WFI.

In twelfth embodiments of the present invention, the multivalent vaccine composition is an all liquid hexavalent vaccine formulation. All liquid hexavalent vaccine formulation comprises of Diphtheria toxoid (D); Tetanus toxoid (T); Inactivated whole cell B. pertussis antigen (wP); Inactivated polio virus sabin strains of Type I, II and III; Inactivated Rota virus (IRV); and H. influenzae type b PRP-TT conjugate and other excipients like Aluminum based adjuvant (Aluminum phosphate, Aluminum hydroxide), 2-phenoxyethanol, L-Histidine and WFI.

In one of the preferred aspect of the twelfth embodiment, the multivalent vaccine composition is an hexavalent vaccine composition wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1-30 Lf; wP is present in an amount in the range of 10-50 IOU; Dose reduced inactivated sabin strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in

the range of 1-30  $\mu\text{g}$ ; H. influenzae type b PRP-TT conjugate is in an amount in the range of 2-20  $\mu\text{g}$  of PRP content; aluminum content ( $\text{Al}^{3+}$ ) is present in an amount in range of 0.4 – 1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg and WFI.

5

In one of the most preferred aspect of the twelfth embodiment, the multivalent vaccine composition is an hexavalent vaccine composition wherein D is present in an amount 22.5 Lf; T is present in an amount 7.5 Lf; wP is present in an amount 15 IOU; Dose reduced inactivated sabin strain of polio virus type 1 is present in an amount 5 D units, type 2 is present in an amount 16 D units, Type 3 is present in an amount 10 D units; IRV is present in an amount 10  $\mu\text{g}$ ; influenzae type b PRP-TT conjugate is in an amount 5  $\mu\text{g}$  ; Aluminum content is present in an amount not more than 0.9 mg; 2-Phenoxyethanol is present in an amount 3.25 mg; L-Histidine is present in the range of 1.55 mg and WFI.

15 In thirteenth embodiments of the present invention, the multivalent vaccine composition is a all liquid hexavalent vaccine formulation. All liquid hexavalent vaccine formulation comprises of Diphtheria toxoid (D); Tetanus toxoid (T); Inactivated whole cell B. pertussis antigen (wP); Inactivated polio virus sabin strains of Type I, II and III; Inactivated Rota virus (IRV); and H. influenzae type b PRP-CRM<sub>197</sub> conjugate and other excipients like  
20 Aluminum based adjuvant (Aluminum phosphate, Aluminum hydroxide), 2-phenoxyethanol, L-Histidine and WFI.

In one of the preferred aspect of the thirteenth embodiment, the multivalent vaccine composition is an hexavalent vaccine composition wherein D is present in an amount in the  
25 range of 1-50 Lf; T is present in an amount in the range of 1-30 Lf; wP is present in an amount in the range of 10-50 IOU; Dose reduced inactivated sabin strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1-30  $\mu\text{g}$ ; H. influenzae type b PRP-CRM<sub>197</sub> conjugate is in an amount in the  
30 range of 2-20  $\mu\text{g}$  of PRP content; aluminum content ( $\text{Al}^{3+}$ ) is present in an amount in range of 0.4 – 1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg and WFI.

In one of the most preferred aspect of the thirteenth embodiment, the multivalent vaccine composition is an hexavalent vaccine composition wherein D is present in an amount 22.5 Lf; T is present in an amount 7.5 Lf; wP is present in an amount 15 IOU; Dose reduced inactivated sabin strain of polio virus type 1 is present in an amount 5 D units, type 2 is present in an amount 16 D units, Type 3 is present in an amount 10 D units; IRV is present in an amount 10 µg; influenzae type b PRP- CRM<sub>197</sub> conjugate is in an amount 10 µg ; Aluminum content is present in an amount not more than 0.9 mg; 2-Phenoxyethanol is present in an amount 3.25 mg; L-Histidine is present in the range of 1.55 mg and WFI.

10 Heptavalent Combination Vaccine composition and its preparation process

In fourteenth embodiment of the present invention, Heptavalent (DTwP-HBsAg-IPV-IRV-Hib) vaccine formulation was prepared as follows:

15 a) IPV (Sabin/Salk strain) bulk and IRV bulk were individually adsorbed on Aluminum hydroxide, followed by pH adjustment to 6.2 – 6.6.

b) HBsAg was adsorbed on Aluminium phosphate, followed by pH adjustment to 6.0 – 6.5.

c) D was adsorbed on Aluminum phosphate, followed by pH adjustment to 5.5 – 6.5 and addition of T.

20 d) Solution obtained in step b and c, followed by blending agitation at room temperature for 18 – 24 hours.

e) Above mixtures [as obtained in step a and d] were added, followed by pH adjustment to 6.4 – 6.6 and agitation at RT for 60 minutes.

25 f) wP antigen and Histidine were added to the above mixture, followed by agitation for 60 minutes and left in static condition for overnight at 2 – 8 °C.

g) Hib PRP protein conjugate and 2-PE were added to the mixture obtained in step f at 2 – 8 °C, followed by pH adjustment to 6.4 – 6.6.

h) NaCl and WFI (q.s.) were added to the mixture obtained in step g, followed by agitation for 2 hours.

30 In fifteenth embodiment of the present invention, the multivalent vaccine composition is a all liquid heptavalent vaccine formulation. All liquid heptavalent vaccine formulation comprises of Diphtheria toxoid (D); Tetanus toxoid (T); Inactivated whole cell B. pertussis antigen (wP); Inactivated polio virus salk strains of Type I, II and III; Inactivated Rota virus

(IRV); and H. influenzae type b PRP-TT conjugate; Hepatitis B surface antigen (HBsAg) and other excipients like Aluminum based adjuvant (Aluminum phosphate, Aluminum hydroxide), 2-phenoxyethanol, L-Histidine and WFI.

5 In one of the preferred aspect of the fifteenth embodiment, the multivalent vaccine composition is an heptavalent vaccine composition wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1-30 Lf; wP is present in an amount in the range of 10-50 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D  
10 antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1-30 µg; H. influenzae type b PRP-TT conjugate is present in an amount in the range of 2 – 20 µg of PRP content; Hepatitis B surface antigen (HBsAg) is present in an amount in the range of 5 – 30 µg; aluminum content ( $Al^{3+}$ ) is present in an amount in range of 0.4 – 1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-  
15 Histidine is present in the range of 0.5 – 5 mg and WFI.

In one of the most preferred aspect of the fifteenth embodiment, the multivalent vaccine composition is an heptavalent vaccine composition wherein D is present in an amount 22.5 Lf; T is present in an amount 7.5 Lf; wP is present in an amount 15 IOU; Dose reduced  
20 inactivated Salk strain of polio virus type 1 is present in an amount 10 D units, type 2 is present in an amount 2 D units, Type 3 is present in an amount 10 or 16 D units; IRV is present in an amount 10 µg; influenzae type b PRP-TT conjugate is in an amount 5 µg ; Hepatitis B surface antigen (HBsAg) is present in an amount 12.5 µg; Aluminum content is present in an amount not more than 0.9 mg; 2-Phenoxyethanol is present in an amount 3.25  
25 mg; L-Histidine is present in the range of 1.55 mg and WFI.

In sixteenth embodiment of the present invention, the multivalent vaccine composition is an all liquid heptavalent vaccine formulation. All liquid heptavalent vaccine formulation comprises of Diphtheria toxoid (D); Tetanus toxoid (T); Inactivated whole cell B. pertussis antigen (wP); Inactivated polio virus salk strains of Type I, II and III; Inactivated Rota virus  
30 (IRV); and H. influenzae type b PRP-CRM<sub>197</sub> conjugate; Hepatitis B surface antigen (HBsAg) and other excipients like Aluminum based adjuvant (Aluminum phosphate, Aluminum hydroxide), 2-phenoxyethanol, L-Histidine and WFI.

In one of the preferred aspect of the sixteenth embodiment, the multivalent vaccine composition is an heptavalent vaccine composition wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1-30 Lf; wP is present in an amount in the range of 10-50 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1-30 µg; H. influenzae type b PRP- CRM<sub>197</sub> conjugate is in an amount in the range of 2 – 20 µg of PRP content; Hepatitis B surface antigen (HBsAg) is present in an amount in the range of 5 – 30 µg; aluminum content (Al<sup>3+</sup>) is present in an amount in range of 0.4 – 1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg and WFI.

In one of the most preferred aspect of the sixteenth embodiment, the multivalent vaccine composition is an heptavalent vaccine composition wherein D is present in an amount 22.5 Lf; T is present in an amount 7.5 Lf; wP is present in an amount 15 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount 10 D units, type 2 is present in an amount 2 D units, Type 3 is present in an amount 10 or 16 D units; IRV is present in an amount 10 µg; influenzae type b PRP- CRM<sub>197</sub> conjugate is in an amount 10 µg of PRP content; Hepatitis B surface antigen (HBsAg) is present in an amount 12.5 µg; Aluminum content is present in an amount not more than 0.9 mg; 2-Phenoxyethanol is present in an amount 3.25 mg; L-Histidine is present in the range of 1.55 mg and WFI.

In seventeenth embodiments of the present invention, the multivalent vaccine composition is a all liquid heptavalent vaccine formulation. All liquid heptavalent vaccine formulation comprises of Diphtheria toxoid (D); Tetanus toxoid (T); Inactivated whole cell B. pertussis antigen (wP); Inactivated polio virus sabin strains of Type I, II and III; Inactivated Rota virus (IRV); and H. influenzae type b PRP-TT conjugate; Hepatitis B surface antigen (HBsAg) and other excipients like Aluminum based adjuvant (Aluminum phosphate, Aluminum hydroxide), 2-phenoxyethanol, L-Histidine and WFI.

In one of the preferred aspect of the seventeenth embodiment, the multivalent vaccine composition is an heptavalent vaccine composition wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1-30 Lf; wP is present in an amount in the range of 10-50 IOU; Dose reduced inactivated sabin strain of polio virus type

1 is present in an amount in the range of 1 – 20 D units, type 2 in the range of 1 - 20 D units, Type 3 in the range of 1 – 20 D units; IRV is present in an amount in the range of 1-30µg; H. influenzae type b PRP-TT conjugate is in an amount in the range of 2-20 µg of PRP content; Hepatitis B surface antigen (HBsAg) is present in an amount in the range of 5 – 30 µg; 5 aluminum content ( $Al^{3+}$ ) is present in an amount in range of 0.4 – 1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg and WFI.

10 In one of the most preferred aspect of the seventeenth embodiment, the multivalent vaccine composition is an heptavalent vaccine composition wherein D is present in an amount 22.5 Lf; T is present in an amount 7.5 Lf; wP is present in an amount 15 IOU; Dose reduced inactivated sabin strain of polio virus type 1 is present in an amount 5 D units, type 2 is present in an amount 16 D units, Type 3 is present in an amount 10 D units; IRV is present in an amount 10 µg; H. influenzae type b PRP-TT conjugate is in an amount 5 µg of PRP 15 content; Hepatitis B surface antigen (HBsAg) is present in an amount 12.5 µg; Aluminum content is present in an amount not more than 0.9 mg; 2-Phenoxyethanol is present in an amount 3.25 mg; L-Histidine is present in the range of 1.55 mg and WFI.

20 In eighteenth embodiments of the present invention, the multivalent vaccine composition is a all liquid heptavalent vaccine formulation. All liquid heptavalent vaccine formulation comprises of Diphtheria toxoid (D); Tetanus toxoid (T); Inactivated whole cell B. pertussis antigen (wP); Inactivated polio virus sabin strains of Type I, II and III; Inactivated Rota virus (IRV); H. influenzae type b PRP-CRM<sub>197</sub> conjugate; Hepatitis B surface antigen (HBsAg) and other excipients like Aluminum based adjuvant (Aluminum phosphate, 25 Aluminum hydroxide), 2-phenoxyethanol, L-Histidine and WFI.

30 In one of the preferred aspect of the eighteenth embodiment, the multivalent vaccine composition is an heptavalent vaccine composition wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1-30 Lf; wP is present in an amount in the range of 10-50 IOU; Dose reduced inactivated sabin strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1 – 30 µg; H. influenzae type b PRP- CRM<sub>197</sub> conjugate is in an amount in the range of 2-20 µg of PRP content; Hepatitis B surface antigen (HBsAg) is present in an

amount in the range of 5 – 30 µg; aluminum content ( $Al^{3+}$ ) is present in an amount in range of 0.4 – 1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg and WFI.

5 In one of the most preferred aspect of the eighteenth embodiment, the multivalent vaccine composition is an heptavalent vaccine composition wherein D is present in an amount 22.5 Lf; T is present in an amount 7.5 Lf; wP is present in an amount 15 IOU; Dose reduced inactivated sabin strain of polio virus type 1 is present in an amount 5 D antigen units, type 2 is present in an amount 16 D antigen units, Type 3 is present in an amount 10 D antigen  
10 units; IRV is present in an amount 10 µg; influenzae type b PRP- CRM<sub>197</sub> conjugate is in an amount 10 µg of PRP content; Hepatitis B surface antigen (HBsAg) is present in an amount 12.5 µg; Aluminum content is present in an amount not more than 0.9 mg; 2-Phenoxyethanol is present in an amount 3.25 mg; L-Histidine is present in the range of 1.55 mg and WFI.

15

In nineteenth embodiment of the present invention, the combination vaccine composition/formulation comprises of one or more preservative selected from the group consisting of Benzethonium chloride (Phemerol), thiomersal, Phenol and 2- phenoxyethanol (2-PE). More preferably, the combination vaccine composition/formulation comprise of 2-  
20 phenoxyethanol (2-PE) as preservative.

In twentieth embodiment of the present invention, the combination vaccine composition/formulation contain one or more pharmaceutically acceptable excipients selected from the group consisting of sugars and polyols, surfactants, polymers, salts,  
25 aminoacids, pH modifiers, etc.

In first aspect of the twentieth embodiment, sugars and polyols includes sucrose, trehalose, lactose, maltose, galactose, mannitol, sorbitol, glycerol, etc. In second aspect of the twentieth embodiment, surfactants include non-ionic surfactants such as polysorbate 20, polysorbate 80, etc. In third aspect of the twentieth embodiment polymers include dextran,  
30 carboxymethylcellulose, hyaluronic acid, cyclodextrin, etc. Examples of the salts may include NaCl, MgCl<sub>2</sub>, KCl, CaCl<sub>2</sub>, etc. In fourth aspect of the twentieth embodiment amino acids includes Arginine, Glycine, Histidine, etc. In fifth aspect of the twentieth embodiment pH modifiers includes sodium hydroxide, hydrochloric acid, etc.

In twenty-first embodiment of the present invention, the pH of the final combination vaccine composition/formulation is in the range of pH 6.0 to pH 7.5; more preferably in the range of pH 6.2 to pH 7.2; and most preferably in the range of pH 6.4 to pH 6.6.

## 5 Examples

### **Example 1: Preparation of Dose Reduced Inactivated Polio Virus (Salk / Sabin) antigen**

**Serum Institute of India** has developed inactivation and adsorption of Inactivated polio virus as per following protocol:

- 10 \* CCL81-VERO (Monkey kidney) cell were used as host cells for the growing of polio viruses i.e. sabin and salk strains.
- \* Purification of IPV
  - \* Clarified harvest pool was concentrated to 10X using tangential flow filtration system with 100 KDa cassettes (0.5m<sup>2</sup>) and then diafiltered 3 times of harvest volume with phosphate buffer (40 mM , pH : 7.0)
  - 15 \* The concentrate was purified by Ion Exchange Chromatography (IEC). 10X TFF concentrate was passed through DEAE Sepharose fast flow (Weak-Anion exchanger) packed in column xk- 26 using Akta explorer (GE Healthcare). Negatively charged impurities were bound to the column whereas polio virus was collected in flow through with phosphate buffer 40
  - 20 mM.
  - \* To minimize the loss of antigen in a quite cumbersome inactivation procedure (13days), purified virus pool was buffer exchanged from phosphate buffer to TRIS buffer (40mM, pH:7) with TFF system [100 KDa ,0.1 m2). The purified virus pool was exchanged with three volumes of tris buffer.
- 25 \* Inactivation of IPV
  - \* 10X concentrated M-199 with 0.5% glycine were added so as to achieve final concentration 1X. Inactivation agent formalin (0.025%) was added into purified virus bulk while constant mixing. Inactivation was carried out at 37°C while continuous stirring for 13 days containing 0.22u filtration on 7th
  - 30 day and 13th day.

### **Result and Conclusion**

When formaldehyde inactivation methods were particularly carried out in presence of phosphate buffer, significant D-antigen losses were observed for Sabin and Salk strains, whereas it was found that formaldehyde inactivation in presence of TRIS buffer resulted in

35 minimum loss of D-antigen.

	D – antigen content (40 mM Phosphate buffer during inactivation)	D – antigen content (40 mM Tris buffer during inactivation)
Type I	52.70 DU/ml	408.19 DU/ml
Type II	22.63 DU/ml	180.20 DU/ml
Type III	4.21 DU/ml	21.50 DU/ml

**Example 2: Preparation of Injectable heat Inactivated Rotavirus (IRV) antigen**

Rotavirus strain (CDC-9) as disclosed in PCT Patent Application No. PCT/US2010/034537 entitled “New Human Rotavirus Strains and Vaccines”, filed May 12, 2010; PCT Patent Application No. PCT/US2008/075239 entitled “Thermal Inactivation of Rotavirus”, filed September 4, 2008 was used.

Centers for Disease Control and Prevention (CDC) has developed a method for rotavirus inactivation. CDC has also developed assay for testing rotavirus specific IgG and neutralizing Antibodies.

- 10       • Rota virus (CDC-9 strain) was cultured using Vero cells (CCL-81) as host cells and the harvest was clarified using 30+2 μ filter to remove cell debris.
- The clarified harvest was treated with Benzonase (5000 units per litre) with incubation at 37 °C for 4 hours with continuous stirring.
- Benzonase treated bulk was further 10X concentrate and 4X diafiltered using ‘HBSS (Hanks Balanced Salt Solution) + 10% sorbitol’ with 100 KDa cassettes.
- 15       • The diafiltered bulk was dialysed using a dilution buffer and was further purified using affinity chromatography (cellufine sulfate resin).
- Inactivation of purified CDC-9 was done using heat at 60 °C for 5 hrs with one change of container after two hours. The inactivated CDC-9 bulk was stored at -80°C
- 20       until further use.

**Example 3 : Purification of Diphtheria toxoid**

Diphtheria toxoid was purified using Gel filtration chromatography with process parameters set as below:

**Table 1: Process Parameters**

Sr. No.	Parameter	Details
1	Used Native Bulk D	--
2	Content (Native Bulk D) by Lowry's assay	11mg/ml
3	LF/ml	3000
4	Method of Purification	Gel Filtration Chromatography (GFC)
5	Resin	Sephacryl S-300 HR
6	Column Used	XK 26/70cm
7	Column Packed bed height	~50cm
8	Linear Flow rate	1 – 3 ml/min
9	Sample (D ) loading	4% of total bed volume
10	Fraction Collection	5ml each (2min)
11	Analysis	Lowry's assay, LF estimation, % Monomer

Fractions no 6 to 11 were pooled and analyzed for monomer content. (Refer figure 1).

#### Results & Interpretation:

- 5 Multiple runs were performed using above same parameters. CRM<sub>197</sub> bulk concentrate was used as a marker to compare % monomer content. Monomeric CRM<sub>197</sub> can be considered purest form of DT. The percent monomer content was found to be in the range of 80 – 90 %.

**Table 2 : % Recovery & Monomer content of purified DT obtained**

Sr. No.	Sample	Protein Conc. (mg/mL)	% Monomer	% Recovery
1	Native DT	---	67.19	--
2	Native CRM	---	86.96	--

3	GFC DT FR 8	2.03	83.21	Injected DT Qty 120mg
4	GFC DT FR 9	3.38	87.15	
5	GFC DT FR 10	4.08	87.24	
6	GFC DT FR 11	3.52	86.60	Obtained Qty 75.1mg (62.5%)
7	GFC DT FR 12	2.01	89.97	
8	GFC DT FR 10-11	3.83	86.03	31.6%
9	GFC DT FR 9-12	2.96	87.42	48.9%
10	GFC DT FR 7-13	2.19	86.24	63.3%

**Example 4 : Purification of Tetanus Toxoid**

Tetanus toxoid was purified using Gel filtration chromatography/ HIC (Phenyl Sepharose) with process parameters set as below:

5 **Table 3: Process Parameters**

Sr. No.	Parameter	Details
1	Used Native Bulk T	--
2	Content (Native Bulk T) by Lowry's assay	11mg/ml
3	LF/ml	3000
4	Method of Purification	Gel Filtration Chromatography (GFC)
5	Resin	Sephacryl S-300 HR
6	Column Used	XK 26/70cm
7	Column Packed bed height	~50cm

8	Linear Flow rate	1 – 3 ml/min
9	Sample (T ) loading	4% of total bed volume
10	Fraction Collection	5ml each (2min)
11	Analysis	Lowry's assay, LF estimation, % Monomer

### Results:

Multiple runs were performed using above same parameters. The percent monomer content was found to be in the range of 80 – 90 %.

### 5 Example 5: Preparation of Hib PRP- Protein conjugate

PRP polysaccharide was produced as follows:

H. Influenzae type-b bacteria was grown in semi synthetic media under certain conditions of temperature, agitation and optical density etc. PRP is an outer membrane bound polysaccharide, gets released into the medium during the fermentation under agitation condition. Fermented biomass separated broth contains crude PRP, which is again purified by precipitation using a detergent N, N, N-trimethyl-1-hexadecanaminium bromide, followed by ethanol gradient precipitation and filtration. Final purified PRP polysaccharide was tested for meeting the specifications like endotoxin, nucleic acid and protein as per the WHO, BP, EP, IP etc.

15 Hib PRP –protein conjugate was prepared as follows:

The polysaccharide conjugate was prepared by coupling of PRP polysaccharide with a CRM<sub>197</sub> carrier protein. The input ratio of reactants i.e. PRP polysaccharide, CDAP and CRM<sub>197</sub> was selected at 1:1.5:1 ratio for conjugation reaction. During conjugation, purified PRP polysaccharide was depolymerized using an alkaline buffer (0.4M Carb-Bicarbonate buffer, pH 10.5 ±0.1) to achieve size reduced PRP. Size reduced PRP is treated for cyanylation using CDAP (1-cyano-4-dimethylamino pyridinium tetrafluoroborate) chemistry to form a cyanate ester. The activated cyanylated polysaccharide may thus be coupled directly with amino group on the carrier protein CRM<sub>197</sub>. The degree of conversion of Hib conjugate was confirmed by the HPLC. The conjugation reaction was quenched by achieving the desired level of conversion of conjugate with the specification of not less than 65% conversion of Hib conjugate, and then conjugate reaction was neutralized by Glycine (2M) addition. The Hib PRP-CRM<sub>197</sub> Conjugate is purified on ultra filtration membrane filters (300kDa and 100kDa) to remove nonreactive reagents and by-products. Final conjugate bulk was 0.22 µm filtered and stored at 2-8°C.

30 Quality characteristics of Hib PRP-CRM<sub>197</sub> conjugate antigen obtained were as follow:

PRP content (mg/mL): 1.49

Protein content (mg/mL): 2.98

Ratio (Ps : Protein) : 0.52

Free PRP (%) : 1.77

5 PMW (kD) : 983

Avg MW (kD) : 752

**Example 6: Composition of Bivalent (IPV-IRV vaccine)**

Serum Institute of India has developed bivalent composition comprising dose reduced inactivated polio virus and Inactivated Rotavirus as per following protocol:

10 Composition of the bivalent vaccine is as under

**Table 4 Bivalent Composition**

Components	Bivalent Vaccine Composition I (Salk IPV + IRV)	Bivalent Vaccine Composition II (Salk IPV + IRV)	Bivalent Vaccine Composition III (Salk IPV + IRV)	Bivalent Vaccine Composition IV (Sabin IPV + IRV)
Antigen content – IPV	Type 1: ≥ 8 DU/dose Type 2: ≥ 2 DU/dose Type 3: ≥ 5 DU/dose	Type 1: ≥ 10 DU/dose Type 2: ≥ 2 DU/dose Type 3: ≥ 10 DU/dose	Type 1: ≥ 10 DU/dose Type 2: ≥ 2 DU/dose Type 3: ≥ 16 DU/dose	Type 1: ≥ 5DU/dose Type 2: ≥ 16DU/dose Type 3: ≥ 10DU/dose
Antigen content – IRV	Total Protein ≥10mcg /dose	Total Protein ≥10mcg /dose	Total Protein ≥10mcg /dose	Total Protein ≥10mcg /dose
Alum	0.8mg/dose	0.8mg/dose	0.8mg/dose	0.8mg/dose

**Example 7: Preparation of Bivalent (IPV-IRV) vaccine**

The bivalent (IPV-IRV) vaccine was prepared as per below procedure:

15 • Adsorption of IPV

- \* Take desired volume of Al (OH)<sub>3</sub> in a vessel.
  - \* Add desired volume of monovalent Salk/Sabin IPV bulk and make final volume with diluent.
  - \* Adjust the final formulation pH to 6.5 with 1 N NaOH/1N HCl.
- 5
- \* Keep the monovalent formulation bulks on magnetic stirrer/rocker overnight at 2-8°C.
- \* **Adsorption of IRV**
    - \* Take desired volume of Al (OH)<sub>3</sub> in a vessel.
    - \* Add desired volume of IRV bulk and make final volume with diluents.
- 10
- \* Adjust the final formulation pH to 6.5 with 1 N NaOH/1N HCl.
  - \* Keep the monovalent formulation bulks on magnetic stirrer/rocker overnight at 2-8°C.
- \* **Formulation of Bivalent (IPV-IRV) Vaccine**
    - \* Mix the monovalent bulks of IPV and IRV formulations.
- 15
- \* Keep at 2-8°C on rocker for 2 Hrs.
  - \* Store the final formulation at 2-8°C until further use.

**Example 8: Efficacy Testing of Bivalent Vaccine**

Potency of bivalent vaccine was examined by testing serum samples for neutralizing antibody against polio virus Sabin type 1, 2, and 3, as well as rotavirus strain Wa using  
 20 microneutralization assays. Neutralization titers against polio viruses are reported in log<sub>2</sub> format. A neutralization titer of 2.5 is considered negative. For rotavirus, a neutralization titer <20 is considered negative.

**Table 5**

	Sample ID	Sabin 1		Sabin 2		Sabin 3		IRV (Wa)	
		D0	D42	D0	D42	D0	D42	D0	D42
Salk 8-2-5 + IRV 10ug	7A	2.5	6.17	2.5	10.5	2.5	7.83	<20	320
	7B	2.5	4.5	2.5	7.17	2.5	2.5	<20	1280
	8A	2.5	7.83	2.5	9.5	2.5	8.83	<20	320
	8B	2.5	8.5	2.5	10.5	2.5	6.5	<20	160
Salk 5-2-5 + IRV 10ug	9A	2.5	5.5	2.5	10.5	2.5	3.5	<20	640
	9B	2.5	2.5	2.5	8.83	2.5	5.83	<20	640
Sabin 5-16-10 + IRV 10ug	10A	2.5	7.5	2.5	9.5	2.5	6.5	<20	640
	10B	2.5	10.5	2.5	10.5	2.5	10.5	<20	320
	11A	2.5	10.5	2.5	10.5	2.5	10.5	<20	640

	11B	2.5	10.5	2.5	10.5	2.5	9.17	<20	640
Sabin 2.5-8-5 + IRV 10ug	12A	2.5	10.5	2.5	10.5	2.5	8.83	<20	320
	12B	2.5	10.5	2.5	10.5	2.5	8.17	<20	80
Rota Live (Log 5.5 FFU)	15A	2.5	2.5	2.5	2.5	2.5	2.5	<20	320
	15B	2.5	2.5	2.5	2.5	2.5	2.5	<20	640
Negative	17A	2.5	2.5	2.5	2.5	2.5	2.5	<20	<20
	17B	2.5	2.5	2.5	2.5	2.5	2.5	<20	<20
	control s	6.5		4.83		4.17		<20 (negative control)	
		6.5		5.17		4.5		160 (positive control 1)	
		6.17		5.5		4.5		1280 (Positive control 2)	
		5.83		4.5		5.5			

The digits (eg 8-2-5) in column A denotes the D antigen units of polio Types 1-2-3 respectively. Each Guinea Pig (7A to 12 B) received three doses of combined vaccine containing IPV and 10ug of inactivated rotavirus antigen (IRV) on day 1, Day 14 and Day 28 and the serum samples were collected on day 42. Guinea pig no 15A and 15B received three doses of live rotavirus (log 5.5FFU or 10ug) as considered as positive control. In negative control group (17A and 17B) only the formulation containing alum without any antigen was used for immunization.

Table 6

SNT for Trivalent Salk+Rota 1Dose and 2 Dose											
Group 7: Salk+Rota 8-2-5 (1 Dose)				Group 8: Salk+Rota 8-2-5 (2 Dose)				Group 9: Salk+Rota 5-2-5 (2 Dose)			
Rat No	Typ e 1	Typ e 2	Typ e 3	Rat No	Typ e 1	Typ e 2	Typ e 3	Rat No	Type 1	Type 2	Type 3
1	2	7	7	1	10	8	11	1	3	9	12
2	3	7	9	2	7	8	10	2	7	6	12
3	4	7	8	3	7	7	7	3	7	8	10
4	4	6	10	4	10	7	10	4	11	9	8
5	0	7	8	5	9	7	12	5	5	6	10
6	0	9	10	6	5	8	9	6	10	9	12
7	5	7	10	7	5	6	10	7	6	6	12
8	8	9	6	8	10	8	11	8	2	10	12
9	4	8	5	9	6	9	11	9	9	9	10
10	6	8	10	10	7	9	10	10	5	NS	NS

Table 7

SNT for Trivalent Sabin+Rota 1Dose and 2 Dose											
Group 10: Sabin+Rota 5-16-10 (1 Dose)				Group 11: Sabin+Rota 5-16-10 (2 Dose)				Group 12: Sabin+Rota 2.5-8-5 (2 Dose)			
Rat No	Type 1	Type 2	Type 3	Rat No	Type 1	Type 2	Type 3	Rat No	Type 1	Type 2	Type 3
1	7	4	11	1	8	7	12	1	5	4	11
2	10	5	11	2	5	7	NS	2	7	2	12
3	7	3	10	3	8	4	12	3	6	6	9
4	8	5	11	4	6	7	12	4	6	8	9
5	7	4	11	5	8	7	12	5	7	5	8
6	8	4	11	6	8	7	12	6	5	6	12
7	6	3	12	7	8	4	10	7	8	6	10
8	11	5	12	8	7	4	11	8	8	6	11
9	7	7	10	9	8	4	12	9	10	7	12
10	9	4	12	10	6	3	10	10	NS	NS	NS

Group 13: Salk Commercial (1 Dose)				Group 14: Salk Commercial (2 Dose)				Group No. 16 Negative Control			
Rat No	Type 1	Type 2	Type 3	Rat No	Type 1	Type 2	Type 3	Rat No	Type 1	Type 2	Type 3
1	4	7	2	1	6	7	NS	1	0	0	0
2	0	4	6	2	3	8	11	2	0	0	0
3	0	6	5	3	1	7	8	3	0	0	0
4	4	8	9	4	7	8	9	4	0	0	0
5	0	7	3	5	2	5	7	5	0	0	0
6	3	6	3	6	7	8	10	6	0	0	0
7	3	6	6	7	7	6	9	7	0	0	0
8	0	4	6	8	12	7	9	8	0	0	0
9	5	8	5	9	10	9	11	9	0	0	0
10	0	4	5	10	5	8	7	10	0	0	0

## Result and Interpretation:

1. Bivalent vaccine (IPV+ IRV) give significantly higher seroconversion on day 42 as compare to Day 0.
- 5 2. Single dose of trivalent Sabin IPV developed at SIIL having 5:16:10 DU with alum gives better seroconversion as compared to commercial IPV.
3. Double dose of trivalent Sabin IPV developed at SIIL having 2.5:8:5 DU with alum gives excellent seroconversion as compared to commercial IPV.
- 10 4. Single dose of trivalent Salk IPV formulated at SIIL having 8:2:5 DU with alum gives better seroconversion as compared to commercial IPV.
5. Double dose of trivalent Sabin IPV formulated at SIIL having 5:2:5 DU with alum gives excellent seroconversion as compared to commercial IPV.

Example 9: Hexavalent Combination Vaccine Compositions comprising Dose reduced IPV, Inactivated rotavirus, D, T, wP, and Hib PRP - Protein conjugate are as given below:

Table 8: Hexavalent Formulation-1 having dose reduced Salk IPV

S. NO	FORMULATION COMPONENTS	Formulati on 1A	Formulati on 1B	Formulati on 1C	Formulati on 1D	Formulati on 1E	Formulati on 1F	Formulati on 1G	Formulati on 1H
1	Diphtheria Toxoid (D)	22.5 Lf							
2	Tetanus toxoid (T)	7.5 Lf							
3	Inactivated <i>B. pertussis</i> antigen (wP)	15 IOU							
4	Inactivated Salk Strain of Polio Virus								
	Type I (D antigen units)	10	7.5	8	10	10	7.5	5	10
	Type II (D antigen units)	2	16	2	2	2	16	2	2
	Type III (D antigen units)	10	10	5	5	12	10	5	16
5	Inactivated Rota virus (IRV)	10 µg							
6	<i>H. Influenzae</i> b PRP- CRM <sub>197</sub> conjugate	10 µg of PRP content							
7	Aluminium Content	Not more than 0.9 mg of Al <sup>3+</sup>							
8	2-Phenoxyethanol	3.25 mg							
9	L-Histidine	1.55 mg							
10	WFI	q.s.							

Table 9 : Hexavalent Formulation-2 having dose reduced Salk IPV

S. NO.	FORMULATION COMPONENTS	Formulat ion 2A	Formulat ion 2B	Formulat ion 2C	Formulat ion 2D	Formulat ion 2E	Formulat ion 2F	Formulat ion 2G	Formulat ion 2H
1	Diphtheria Toxoid (D)	22.5 Lf							
2	Tetanus toxoid (T)	7.5 Lf							
3	Inactivated <i>B. pertussis</i> antigen (wP)	15 IOU							
4	Inactivated Salk Strain of Polio Virus								
	Type I (D antigen units)	10	7.5	8	10	10	7.5	5	10
	Type II (D antigen units)	2	16	2	2	2	16	2	2
	Type III (D antigen units)	10	10	5	5	12	10	5	16
5	Inactivated Rota virus (IRV)	10 µg							
6	H. Influenzae b PRP-IT conjugate	5 µg of PRP content							
7	Aluminium Content	Not more than 0.9 mg of Al <sup>3+</sup>							
8	2-Phenoxyethanol	3.25 mg							
9	L-Histidine	1.55 mg							
10	WFI	q.s.							

Table 10 : Hexavalent Formulation-3 having dose reduced Sabin IPV

S. NO.	FORMULATION COMPONENTS	Formulation 3A	Formulation 3B	Formulation 3C
1	Diphtheria Toxoid (D)	22.5 Lf		
2	Tetanus toxoid (T)	7.5 Lf		
3	Inactivated <i>B. pertussis</i> antigen (wP)	15 IOU		
4	Inactivated Sabin Strain of Polio Virus			
	Type I (D antigen units)	5	2.5	5
	Type II (D antigen units)	16	8	8
	Type III (D antigen units)	10	5	10
5	Inactivated Rota virus (IRV)	10 µg		
6	<i>H. Influenzae</i> b PRP- CRM <sub>197</sub> conjugate	10 µg of PRP content		
7	Aluminium Content	Not more than 0.9 mg of Al <sup>3+</sup>		
8	2-Phenoxyethanol	3.25 mg		
9	L-Histidine	1.55 mg		
10	WFI	q.s.		

Table 11 : Hexavalent Formulation-4 having dose reduced Sabin IPV

S. NO.	FORMULATION COMPONENTS	Formulation 4A	Formulation 4B	Formulation 4C
1	Diphtheria Toxoid (D)	22.5 Lf		
2	Tetanus toxoid (T)	7.5 Lf		
3	Inactivated <i>B. pertussis</i> antigen (wP)	15 IOU		
4	Inactivated Sabin Strain of Polio Virus			
	Type I (D antigen units)	5	2.5	5
	Type II (D antigen units)	16	8	8
	Type III (D antigen units)	10	5	10
5	Inactivated Rota virus (IRV)	10 µg		
6	<i>H. Influenzae</i> b PRP-TT conjugate	5 µg of PRP content		
7	Aluminium Content	Not more than 0.9 mg of Al <sup>3+</sup>		
8	2-Phenoxyethanol	3.25 mg		
9	L-Histidine	1.55 mg		
10	WFI	q.s.		

**Example 10: Process for preparation of Hexavalent Combination Vaccine Compositions comprising Dose reduced IPV, Inactivated rotavirus, D, T, wP, and Hib PRP - Protein conjugate is as given below:**

- a) IPV (Sabin/Salk strain) bulk and IRV bulk were individually adsorbed on Aluminum hydroxide, followed by pH adjustment to 6.2 – 6.6.
- b) D was adsorbed on Aluminum phosphate, followed by pH adjustment to 5.5 – 6.5, addition of T and blending by agitation at room temperature for 18 – 24 hours.
- c) The solutions obtained in step a and b were mixed, followed by pH adjustment to 6.4 – 6.6 and agitation at RT for 60 minutes.
- d) wP antigen and Histidine were added to the above mixture, followed by agitation for 60 minutes and left in static condition for overnight at 2 – 8 °C.
- e) Hib PRP conjugate and 2-PE were added to the mixture obtained in step d at 2 – 8 °C, followed by pH adjustment to 6.4 – 6.6.
- f) NaCl and WFI (q.s.) were added to the mixture obtained in step e, followed by agitation for 2 hours.

Hib PRP -carrier protein conjugate prepared by using novel conjugation process and subsequently blended at low temperature in presence of a stabilizer shows greater stability with minimum free PRP release and improved immunogenicity. Also, addition of whole cell pertussis antigen at a later stage in a blend minimizes hydrolysis based degradation and provides a stable and immunogenic wP antigen.

Example 11: Heptavalent Combination Vaccine Compositions comprising Dose reduced IPV, Inactivated rotavirus, D, T, wP, HBsAg, and Hib PRP - Protein conjugate are as given below:

Table 12: Heptavalent Formulation-5 having dose reduced Salk IPV

S. NO	FORMULATION COMPONENTS	Formulati on 5A	Formulati on 5B	Formulati on 5C	Formulati on 5D	Formulati on 5E	Formulati on 5F	Formulati on 5G	Formulati on 5H	
1	Diphtheria Toxoid (D)	22.5 Lf								
2	Tetanus toxoid (T)	7.5 Lf								
3	Inactivated <i>B. pertussis</i> antigen (wP)	15 IOU								
	Inactivated Salk Strain of Polio Virus									
4	Type I (D antigen units)	10	7.5	8	10	10	7.5	5	10	
	Type II (D antigen units)	2	16	2	2	2	16	2	2	
	Type III (D antigen units)	10	10	5	5	12	10	5	16	
5	Inactivated Rota virus (IRV)	10 µg								
6	<i>H. Influenzae b</i> PRP- CRM <sub>197</sub> conjugate	10 µg of PRP content								
7	Hepatitis B surface antigen (HbsAg)	12.5 µg								
8	Aluminium Content	Not more than 0.9 mg of Al <sup>3+</sup>								
9	2-Phenoxyethanol	3.25 mg								
10	L-Histidine	1.55 mg								
11	WFI	q.s.								

Table 7 : Heptavalent Formulation-6 having dose reduced Salk IPV

S. NO	FORMULATION COMPONENTS	Formulati on 6A	Formulati on 6B	Formulati on 6C	Formulati on 6D	Formulati on 6E	Formulati on 6F	Formulati on 6G	Formulati on 6H	
1	Diphtheria Toxoid (D)	22.5 Lf								
2	Tetanus toxoid (T)	7.5 Lf								
3	Inactivated <i>B. pertussis</i> antigen (wP)	15 IOU								
	Inactivated Salk Strain of Polio Virus									
4	Type I (D antigen units)	10	7.5	8	10	10	7.5	5	10	
	Type II (D antigen units)	2	16	2	2	2	16	2	2	
	Type III (D antigen units)	10	10	5	5	12	10	5	16	
5	Inactivated Rota virus (IRV)	10 µg								
6	H. Influenzae b PRP-II conjugate	5 µg of PRP content								
7	Hepatitis B surface antigen (HbsAg)	12.5 µg								
8	Aluminium Content	Not more than 0.9 mg of Al <sup>3+</sup>								
9	2-Phenoxyethanol	3.25 mg								
10	L-Histidine	1.55 mg								
11	WFI	q.s.								

Table 8 : Heptavalent Formulation-7 having dose reduced Sabin IPV

S. NO.	FORMULATION COMPONENTS	Formulation n 7A	Formulation n 7B	Formulation n 7C
1	Diphtheria Toxoid (D)	22.5 Lf		
2	Tetanus toxoid (TT)	7.5 Lf		
3	Inactivated <i>B. pertussis</i> antigen (wP)	15 IOU		
4	Inactivated Sabin Strain of Polio Virus			
	Type I (D antigen units)	5	2.5	5
	Type II (D antigen units)	16	8	8
	Type III (D antigen units)	10	5	10
5	Inactivated Rota virus (IRV)	10 µg		
6	<i>H. Influenzae</i> b PRP- CRM <sub>197</sub> conjugate	10 µg of PRP content		
7	Hepatitis B surface antigen (HbsAg)	12.5 µg		
8	Aluminium Content	Not more than 0.9 mg of Al <sup>3+</sup>		
9	2-Phenoxyethanol	3.25 mg		
10	L-Histidine	1.55 mg		
11	WFI	q.s.		

Table 9 : Heptavalent Formulation-8 having dose reduced Sabin IPV

S. NO.	FORMULATION COMPONENTS	Formulation n 8A	Formulation n 8B	Formulation n 8C
1	Diphtheria Toxoid (D)	22.5 Lf		
2	Tetanus toxoid (T)	7.5 Lf		
3	Inactivated <i>B. pertussis</i> antigen (wP)	15 IOU		
4	Inactivated Sabin Strain of Polio Virus			
	Type I (D antigen units)	5	2.5	5
	Type II (D antigen units)	16	8	8
	Type III (D antigen units)	10	5	10
5	Inactivated Rota virus (IRV)	10 µg		
6	<i>H. Influenzae</i> b PRP-TT conjugate	5 µg of PRP content		
7	Hepatitis B surface antigen (HbsAg)	12.5 µg		
8	Aluminium Content	Not more than 0.9 mg of Al <sup>3+</sup>		
9	2-Phenoxyethanol	3.25 mg		
10	L-Histidine	1.55 mg		
11	WFI	q.s.		

**Example 12: Process for preparation of Heptavalent Combination Vaccine Compositions comprising Dose reduced IPV, Inactivated rotavirus, D, T, wP, HBsAg, and Hib PRP - Protein conjugate is as given below:**

- a) IPV (Sabin/Salk strain) bulk and IRV bulk were individually adsorbed on Aluminum hydroxide, followed by pH adjustment to 6.2 – 6.6.
- b) HBsAg was adsorbed on Aluminium phosphate, followed by pH adjustment to 6.0 – 6.5.
- c) D was adsorbed on Aluminum phosphate, followed by pH adjustment to 5.5 – 6.5 and addition of T.
- d) Mix solution obtained in step b and c, followed by blending agitation at room temperature for 18 – 24 hours.
- e) Above mixtures [as obtained in step a and d] were added, followed by pH adjustment to 6.4 – 6.6 and agitation at RT for 60 minutes.
- f) wP antigen and Histidine were added to the above mixture, followed by agitation for 60 minutes and left in static condition for overnight at 2 – 8 °C.
- g) Hib PRP protein conjugate and 2-PE were added to the mixture obtained in step f at 2 – 8 °C, followed by pH adjustment to 6.4 – 6.6.
- h) NaCl and WFI (q.s.) were added to the mixture obtained in step g, followed by agitation for 2 hours.

Hib PRP -carrier protein conjugate prepared by using novel conjugation process and subsequently blended at low temperature in presence of a stabilizer shows greater stability with minimum free PRP release and improved immunogenicity. Also, addition of whole cell pertussis antigen at a later stage in a blend minimizes hydrolysis based degradation and provides a stable and immunogenic wP antigen.

**Claims:**

- 1) A combination vaccine comprising
  - i) inactivated polio virus antigen selected from Salk or Sabin strain;
  - ii) inactivated rotavirus antigen;
  - iii) optionally one or more antigens selected from group comprising of Diphtheria toxoid, Tetanus toxoid, Whole cell pertussis , HBsAg, Hib PRP-Carrier protein conjugate, Neisseria meningitidis A antigen(s), Neisseria meningitidis C antigen(s), Neisseria meningitidis W-135 antigen(s), Neisseria meningitidis Y antigen(s), Neisseria meningitidis X antigen(s), Streptococcus Pneumoniae antigen(s), Neisseria meningitidis B bleb or purified antigen(s), Staphylococcus aureus antigen(s), Anthrax, BCG, Hepatitis A antigen(s), Hepatitis B antigen, Human papilloma virus, Salmonella typhi antigen(s) , acellular pertussis , modified adenylate cyclase, Malaria Antigen (RTS,S), Measles, Mumps, Rubella, Dengue, Zika, Ebola, Chikungunya, Japanese encephalitis, Diarrheal antigens; and
  - iv) one or more adjuvant(s) selected from aluminium salt such as aluminium hydroxide or aluminium phosphate.  
Wherein the polio virus antigen is a dose reduced composition having atleast one inactivated polio virus strain selected from Type 1, Type 2 or Type 3 of Sabin; or Mahoney type 1, MEF Type 2 , or Saukett type 3 of Salk.
- 2) The vaccine as claimed in claim 1, wherein said dose reduced inactivated polio virus antigen is adsorbed on aluminium hydroxide adjuvant having  $Al^{3+}$  concentration between 0.1 – 2.5 mg/dose and percent adsorption of atleast 70 %.
- 3) The vaccine as claimed in Claim 2, wherein said dose reduced inactivated polio virus antigen is adsorbed on aluminium hydroxide adjuvant having  $Al^{3+}$  concentration between 0.1 – 0.7 mg/dose and percent adsorption of atleast 90 %.
- 4) The vaccine as claimed in claim 1, wherein said dose reduced inactivated polio virus antigen is selected from a group comprising of
  - i) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 5-16-10 D-antigen units.

- ii) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 2.5-8-5 D-antigen units.
  - iii) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 5-8-10 D-antigen units.
  - iv) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 7.5-16-10 D-antigen units.
  - v) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 8-2-5 D-antigen units.
  - vi) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-5 D-antigen units.
  - vii) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-10 D-antigen units.
  - viii) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-12 D - antigen units.
  - ix) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-16 D - antigen units.
  - x) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 7.5-16-10 D-antigen units.
  - xi) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 5-2-5 D-antigen units.
- 5) The vaccine as claimed in claim 1, wherein the rotavirus antigen is an injectable heat inactivated rotavirus selected from CDC-9, CDC-66 or any other inactivated rotavirus strains and is adsorbed on aluminium hydroxide adjuvant having  $Al^{3+}$  concentration between 0.1 – 2.5 mg/dose and providing percent adsorption of at least 70%.
- 6) The vaccine as claimed in claim 5, wherein the rotavirus antigen is heat inactivated CDC-9 rotavirus strain and is adsorbed on aluminium hydroxide adjuvant having  $Al^{3+}$  concentration between 0.1 – 0.5 mg/dose and providing a percent adsorption of at least 90 %.
- 7) The vaccine as claimed in claim 1, wherein the D and T antigens are adsorbed onto aluminium phosphate adjuvant.

- 8) The vaccine as claimed in claim 1, wherein the D and T are purified using Gel permeation chromatography with resin selected from the group comprising of Sephacryl S-300 HR, PLgel, Sephacryl S-200HR, Sephadex, Bio-Gel (cross-linked polyacrylamide agarose gel) and Styragel.
- 9) The vaccine as claimed in claim 1, wherein the pertussis antigen is an acellular antigen comprising at least one or more antigens selected from modified adenylate cyclase, Pertussis toxoid (PT), Filamentous hemagglutinin (FHA), Pertactin (P69 or PRN), Fimbrial proteins (FIM 1, 2 and 3).
- 10) The vaccine as claimed in claim 1, wherein the pertussis antigen is an inactivated whole cell pertussis comprising one or more of *Bordetella pertussis* strains 134, 509, 25525 and 6229.
- 11) The vaccine as claimed in claim 1, wherein Hib antigen is Hib PRP polysaccharide conjugated to a carrier protein using a cyanylation conjugation chemistry, wherein said cyanylation reagent is selected from 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyanoimidazole namely (1-CI), 1-cyanobenzotriazole( 1-CBT) or 2-cyanopyridazine-3(2H)one (2-CPO); and carrier protein is selected from a group comprising of CRM<sub>197</sub>, *Diphtheria* toxoid, *Neisseria meningitidis* outer membrane complex, fragment C of *tetanus* toxoid, pertussis toxoid, protein D of *H. influenzae*, *E. coli* LT, *E. coli* ST, and exotoxin A from *Pseudomonas aeruginosa*, outer membrane complex c (OMPC), porins, transferrin binding proteins, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), pneumococcal PhtD, pneumococcal surface proteins BVH-3 and BVH-11, protective antigen (PA) of *Bacillus anthracis* and detoxified edema factor (EF) and lethal factor (LF) of *Bacillus anthracis*, ovalbumin, keyhole limpet hemocyanin (KLH), human serum albumin, bovine serum albumin (BSA) and purified protein derivative of tuberculin (PPD), synthetic peptides, heat shock proteins, pertussis proteins, cytokines, lymphokines, hormones, growth factors, artificial proteins comprising

multiple human CD4+ T cell epitopes from various pathogen-derived antigens such as N 19, iron-uptake proteins, toxin A or B from *C. difficile* and *S. agalactiae* proteins

- 12) The vaccine as claimed in claim 1, wherein HBsAg antigen is a surface antigen of Hepatitis B and is individually adsorbed onto aluminium phosphate.
- 13) The vaccine as claimed in claim 1, wherein vaccine comprises at least one preservative selected from a group consisting of 2-phenoxyethanol, Phenol, Thiomersal, Formaldehyde.
- 14) The vaccine as claimed in claim 1 -- 6, wherein the combination vaccine is a bivalent vaccine composition comprising dose reduced IPV and inactivated IRV.
- 15) The vaccine as claimed in claim 14, wherein the individual concentration of Type 1, Type 2, and Type 3 of Salk strain based IPV is not more than 20 D antigen units.
- 16) The vaccine as claimed in claim 15, wherein the dose concentration of Type 1, Type 2, and Type 3 of Salk strain based IPV is selected from i) 8 D antigen units, 2 D antigen units, 5 D antigen units; ii) 10 D antigen units, 2 D antigen units, 10 D antigen units; and iii) 10 D antigen units, 2 D antigen units, 16 D antigen units.
- 17) The vaccine as claimed in claim 14, wherein the individual concentration of Type 1, Type 2, or Type 3 of Sabin strain based IPV is not more than 20 D antigen units.
- 18) The vaccine as claimed in claim 17, wherein the concentration of Type 1, Type 2, and Type 3 of Sabin strain based IPV is 5-16-10 D antigen units.
- 19) The vaccine as claimed in claim 14 - 18, wherein the concentration of Type 1, Type 2, and Type 3 of Salk or Sabin strain based IPV is a dose as claimed in claim 4.
- 20) The vaccine as claimed in Claim 14, wherein concentration of Inactivated Rota Virus is 10 µg/dose.

- 21) The vaccine as claimed in Claim 14, wherein Alum ( $Al^{3+}$ ) is used as an adjuvant in the concentration not greater than 1 mg/dose.
- 22) The vaccine as claimed in claim 1, comprising D, T, wP, Hib B, IPV and IRV, wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1 – 30 Lf; wP is present in an amount in the range of 10 – 50 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1 – 30  $\mu$ g; H. influenzae type b PRP- protein conjugate is in an amount in the range of 2 – 20  $\mu$ g of PRP content; Total aluminum content ( $Al^{3+}$ ) is present in an amount in the range of 0.4-1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg.
- 23) The vaccine as claimed in claim 22, comprising D, T, wP, Hib B, IPV and IRV, wherein D is present in an amount of about 22.5 Lf; T is present in an amount of about 7.5 Lf; wP is present in an amount of about 15 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount of about 10 D antigen units, type 2 is present in an amount of about 2 D antigen units, Type 3 is present in an amount of about 10 or 16 D antigen units; IRV is present in an amount of about 10  $\mu$ g; H. influenzae type b PRP- TT conjugate is present in an amount of about 5  $\mu$ g of PRP content; Total aluminum content ( $Al^{3+}$ ) is present in an amount of not more than 0.9 mg; 2-Phenoxyethanol is present in an amount of about 3.25 mg; L-Histidine is present in an amount of about 1.55 mg.
- 24) The vaccine as claimed in claim 22, comprising D, T, wP, Hib B, IPV and IRV, wherein D is present in an amount of about 22.5 Lf; T is present in an amount of about 7.5 Lf; wP is present in an amount of about 15 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount of about 10 D antigen units, type 2 is present in an amount of about 2 D antigen units, Type 3 is present in an amount of about 10 or 16 D antigen units; IRV is present in an amount of about 10  $\mu$ g; H. influenzae type b PRP- CRM<sub>197</sub> conjugate is present in an amount of about 10  $\mu$ g of PRP content; Total aluminum content ( $Al^{3+}$ ) is present in an amount of not more

than 0.9 mg; 2-Phenoxyethanol is present in an amount of about 3.25 mg; L-Histidine is present in an amount of about 1.55 mg.

- 25) The vaccine as claimed in claim 1, comprising D, T, wP, Hib B, IPV and IRV, wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1 – 30 Lf; wP is present in an amount in the range of 10 – 50 IOU; Dose reduced inactivated Sabin strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1 – 30 µg; H. influenzae type b PRP- protein conjugate is in an amount in the range of 2 – 20 µg of PRP content; Total aluminum content ( $Al^{3+}$ ) is present in an amount in the range of 0.4-1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg.
- 26) The vaccine as claimed in claim 25, comprising D, T, wP, Hib B, IPV and IRV, wherein D is present in an amount of about 22.5 Lf; T is present in an amount of about 7.5 Lf; wP is present in an amount of about 15 IOU; Dose reduced inactivated Sabin strain of polio virus type 1 is present in an amount of about 5 D antigen units, type 2 is present in an amount of about 16 D antigen units, Type 3 is present in an amount of about 10 D antigen units; IRV is present in an amount of about 10 µg; H. influenzae type b PRP- TT conjugate is present in an amount of about 5 µg of PRP content; Total aluminum content ( $Al^{3+}$ ) is present in an amount of not more than 0.9 mg; 2-Phenoxyethanol is present in an amount of about 3.25 mg; L-Histidine is present in an amount of about 1.55 mg.
- 27) The vaccine as claimed in claim 25, comprising D, T, wP, Hib B, IPV and IRV, wherein D is present in an amount of about 22.5 Lf; T is present in an amount of about 7.5 Lf; wP is present in an amount of about 15 IOU; Dose reduced inactivated Sabin strain of polio virus type 1 is present in an amount of about 5 D antigen units, type 2 is present in an amount of about 16 D antigen units, Type 3 is present in an amount of about 10 D antigen units; IRV is present in an amount of about 10 µg; H. influenzae type b PRP- CRM<sub>197</sub> conjugate is present in an amount of about 10 µg of PRP content; Total aluminum content ( $Al^{3+}$ ) is present in an amount of not more than

0.9 mg; 2-Phenoxyethanol is present in an amount of about 3.25 mg; L-Histidine is present in an amount of about 1.55 mg.

- 28) The vaccine as claimed in claim 1, comprising D, T, wP, Hib B, HBsAg, IPV and IRV, wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1 – 30 Lf; wP is present in an amount in the range of 10 – 50 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1 – 30 µg; H. influenzae type b PRP- protein conjugate is in an amount in the range of 2 – 20 µg of PRP content; Hepatitis B surface antigen (HBsAg) is in an amount in the range of 5 – 30 µg; Total aluminum content ( $Al^{3+}$ ) is present in an amount in the range of 0.4-1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg.
- 29) The vaccine as claimed in claim 28, comprising D, T, wP, Hib B, HBsAg, IPV and IRV, wherein D is present in an amount of about 22.5 Lf; T is present in an amount of about 7.5 Lf; wP is present in an amount of about 15 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount of about 10 D antigen units, type 2 is present in an amount of about 2 D antigen units, Type 3 is present in an amount of about 10 or 16 D antigen units; IRV is present in an amount of about 10 µg; H. influenzae type b PRP- TT conjugate is present in an amount of about 5 µg of PRP content; Hepatitis B surface antigen (HBsAg) is in an amount of about 12.5 µg; Total aluminum content ( $Al^{3+}$ ) is present in an amount of not more than 0.9 mg; 2-Phenoxyethanol is present in an amount of about 3.25 mg; L-Histidine is present in an amount of about 1.55 mg.
- 30) The vaccine as claimed in claim 28, comprising D, T, wP, Hib B, HBsAg, IPV and IRV, wherein D is present in an amount of about 22.5 Lf; T is present in an amount of about 7.5 Lf; wP is present in an amount of about 15 IOU; Dose reduced inactivated Salk strain of polio virus type 1 is present in an amount of about 10 D antigen units, type 2 is present in an amount of about 2 D antigen units, Type 3 is present in an amount of about 10 or 16 D antigen units; IRV is present in an amount of about 10 µg; H. influenzae type b PRP- CRM<sub>197</sub> conjugate is present in an amount of about 10

µg of PRP content; Hepatitis B surface antigen (HBsAg) is in an amount of about 12.5 µg; Total aluminum content ( $Al^{3+}$ ) is present in an amount of not more than 0.9 mg; 2-Phenoxyethanol is present in an amount of about 3.25 mg; L-Histidine is present in an amount of about 1.55 mg.

- 31) The vaccine as claimed in claim 1, comprising D, T, wP, Hib B, HBsAg, IPV and IRV, wherein D is present in an amount in the range of 1-50 Lf; T is present in an amount in the range of 1 – 30 Lf; wP is present in an amount in the range of 10 – 50 IOU; Dose reduced inactivated Sabin strain of polio virus type 1 is present in an amount in the range of 1 – 20 D antigen units, type 2 in the range of 1 – 20 D antigen units, Type 3 in the range of 1 – 20 D antigen units; IRV is present in an amount in the range of 1 – 30 µg; H. influenzae type b PRP- protein conjugate is in an amount in the range of 2 – 20 µg of PRP content; Hepatitis B surface antigen (HBsAg) is in an amount in the range of 5 – 30 µg; Total aluminum content ( $Al^{3+}$ ) is present in an amount in the range of 0.4-1.5 mg; 2-Phenoxyethanol is present in an amount in the range of 2 – 6 mg; L-Histidine is present in the range of 0.5 – 5 mg.
- 32) The vaccine as claimed in claim 31, comprising D, T, wP, Hib B, HBsAg, IPV and IRV; wherein D is present in an amount of about 22.5 Lf; T is present in an amount of about 7.5 Lf; wP is present in an amount of about 15 IOU; Dose reduced inactivated Sabin strain of polio virus type 1 is present in an amount of about 5 D antigen units, type 2 is present in an amount of about 16 D antigen units, Type 3 is present in an amount of about 10 D antigen units; IRV is present in an amount of about 10 µg; H. influenzae type b PRP- TT conjugate is present in an amount of about 5 µg of PRP content; Hepatitis B surface antigen (HBsAg) is in an amount of about 12.5 µg; Total aluminum content ( $Al^{3+}$ ) is present in an amount of not more than 0.9 mg; 2-Phenoxyethanol is present in an amount of about 3.25 mg; L-Histidine is present in an amount of about 1.55 mg.
- 33) The vaccine as claimed in claim 31, comprising D, T, wP, Hib B, HBsAg, IPV and IRV; wherein D is present in an amount of about 22.5 Lf; T is present in an amount of about 7.5 Lf; wP is present in an amount of about 15 IOU; Dose reduced inactivated Sabin strain of polio virus type 1 is present in an amount of about 5 D antigen units,


type 2 is present in an amount of about 16 D antigen units, Type 3 is present in an amount of about 10 D antigen units; IRV is present in an amount of about 10 µg; H. influenzae type b PRP- CRM<sub>197</sub> conjugate is present in an amount of about 10 µg of PRP content; Hepatitis B surface antigen (HBsAg) is in an amount of about 12.5 µg; Total aluminum content (Al<sup>3+</sup>) is present in an amount of not more than 0.9 mg; 2-Phenoxyethanol is present in an amount of about 3.25 mg; L-Histidine is present in an amount of about 1.55 mg.

- 34) The vaccine as claimed in claim 1-33, wherein the IPV and IRV antigens are individually adsorbed on Aluminum hydroxide; and other antigen(s) are either unadsorbed or adsorbed on aluminum salt selected from one or more of Alum Phosphate, Alum hydroxide, and their combination thereof.
- 35) The vaccine as claimed in claim 1-33, wherein the vaccine optionally comprises of excipients selected from the group comprising of Histidine, Sucrose, Glycine, & Sodium Chloride; more preferably Histidine in the concentration range of 5 – 40 mM, most preferably Histidine at concentration of 20 mM.
- 36) A process of manufacturing a combination vaccine as claimed in claim 1 and 14, comprising the steps of:
  - a) Adsorbing IPV (Sabin/Salk strain) bulk and IRV bulk individually on Aluminum hydroxide.
  - b) Mixing Monovalent bulks of IPV and IRV and keeping the mixture at 2 – 8 °C on rocker for 2 hours.
- 37) A process of manufacturing a (hexavalent) combination vaccine as claimed in claim 1 and 22 – 27, comprising the steps of:
  - a) adsorbing IPV (Sabin/Salk strain) bulk and IRV bulk individually on Aluminum hydroxide, followed by pH adjustment to 6.2 – 6.6, more preferably 6.5.
  - b) adsorbing D on Aluminum phosphate, followed by pH adjustment to 5.5 – 6.5 and addition of T and blending by agitation at room temperature for 18 – 24 hours.
  - c) adding the above mixtures [as obtained in step a and step b], followed by pH adjustment to 6.4 – 6.6 and agitation at room temperature for 60 minutes.

- d) adding wP antigen and a stabilizer to the above mixture, followed by agitation for 60 minutes and left in static condition for overnight at 2 – 8 °C.
  - e) adding Hib PRP conjugate and 2-PE to the mixture obtained in step d at 2 – 8 °C, followed by pH adjustment to 6.4 – 6.6.
  - f) adding NaCl and WFI (q.s.) to the mixture obtained in step e, followed by agitation for 2 hours.
- 38) A process of manufacturing a (heptavalent) combination vaccine as claimed in claim 1 and 28 – 33 , comprising the steps of:
- a) adsorbing IPV (Sabin/Salk strain) bulk and IRV bulk individually on Aluminum hydroxide, followed by pH adjustment to 6.2 – 6.6
  - b) adsorbing HBsAg on Aluminium phosphate, followed by pH adjustment to 6.0 – 6.5.
  - c) adsorbing D on Aluminum phosphate, followed by pH adjustment to 5.5 – 6.5 and addition of T.
  - d) blending mixtures obtained in step b and c, by agitation at room temperature for 18-24 hours.
  - e) adding the above mixtures [as obtained in step a and d], followed by pH adjustment to 6.4 – 6.6 and agitation at room temperature for 60 minutes.
  - f) adding wP antigen and stabilizer to the above mixture, followed by agitation for 60 minutes and left in static condition for overnight at 2 – 8 °C.
  - g) adding Hib PRP conjugate and 2-PE to the mixture obtained in step d at 2 – 8 °C, followed by pH adjustment to 6.4 – 6.6.
  - h) adding NaCl and WFI (q.s.) to the mixture obtained in step e, followed by agitation for 2 hours.
- 39) The vaccine as claimed in claim 1 – 38, wherein i) said purified Diphtheria toxoid and Tetanus toxoid obtained by using Gel Permeation chromatography have a monomeric content of atleast 80% ii) said Hib PRP -carrier protein conjugate prepared by using cyanylation conjugation process and subsequently blended at low temperature in presence of a an excipient shows greater stability with minimum free PRP release and improved immunogenicity iii) said whole cell pertussis antigen added at a later stage in a blend minimizes hydrolysis based degradation and provides a stable and immunogenic wP antigen.

Figure 1:

X Axis: Volume (ml)  
Y Axis: UV@280nm (mAU)



INTERNATIONAL SEARCH REPORT

International application No  
PCT/IB2017/055100

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61K39/12  
ADD.  
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
Minimum documentation searched (classification system followed by classification symbols)  
A61K C12N  
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2012/093406 A2 (BHARAT BIOTECH INT LTD [IN]; KUPPUSWAMY GOPINATHAN [IN]; THIAGARAJAN V) 12 July 2012 (2012-07-12)	1,5,7-9, 11-14, 21,35
Y	page 3, line 34 - line 37 page 7, line 11 - line 28 examples 3-5; tables 5,8,9	2-4,6, 10, 15-19, 22-34, 36-39
Y	----- WO 2016/063291 A1 (SERUM INST OF INDIA PRIVATE LTD [IN]) 28 April 2016 (2016-04-28)  claims 1-14; examples 1-6 the whole document  ----- -/--	2-4,6, 10, 15-19, 22-34, 36-39

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search  30 November 2017	Date of mailing of the international search report  11/12/2017
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Lewis, Birgit

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/IB2017/055100

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2008/028956 A1 (GLAXOSMITHKLINE BIOLOG SA) 13 March 2008 (2008-03-13)	10,37-39
A	page 5, line 1827 page 5, line 29 - page 6, line 2 page 6, line 14 - line 17 page 6, line 23 - line 27 page 38, paragraph 2 page 40; table 5 page 40, last paragraph	2-4, 15-19, 34,36
Y	----- BAOMING JIANG ET AL: "Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? : Evidence from animal studies", HUMAN VACCINES AND IMMUNOTHERAPEUTICS, vol. 9, no. 8, 8 August 2013 (2013-08-08), pages 1634-1637, XP055430376, US ISSN: 2164-5515, DOI: 10.4161/hv.24958 abstract page 1635, left-hand column, paragraph 2	6
A	----- ANDREASEN LARS VIBE ET AL: "Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats", VACCINE, vol. 33, no. 15, 17 February 2015 (2015-02-17), pages 1873-1879, XP029213345, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2015.02.011 abstract page 1875 - page 1877	2-4,6, 10, 15-19, 22-34, 36-39
A	----- WANG Y ET AL: "Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 28, no. 33, 26 July 2010 (2010-07-26) , pages 5432-5436, XP027171070, ISSN: 0264-410X [retrieved on 2010-06-15] the whole document	6
A	----- WESTDIJK JANNY ET AL: "Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 31, no. 9, 9 January 2013 (2013-01-09), pages 1298-1304, XP028970802, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2012.12.076 the whole document	1-39
	-----	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2017/055100

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 2012093406	A2	12-07-2012	BR 112013017171 A2	04-10-2016
			CN 103442730 A	11-12-2013
			EP 2661277 A2	13-11-2013
			RU 2013136397 A	10-02-2015
			US 2013280293 A1	24-10-2013
			WO 2012093406 A2	12-07-2012
			ZA 201304606 B	26-03-2014
-----				
WO 2016063291	A1	28-04-2016	AU 2015334495 A1	25-05-2017
			CA 2963897 A1	28-04-2016
			CN 106999569 A	01-08-2017
			EP 3204494 A1	16-08-2017
			JP 2017533899 A	16-11-2017
			KR 20170063947 A	08-06-2017
			PE 11322017 A1	09-08-2017
			PH 12017500627 A1	25-09-2017
			SG 11201702838S A	30-05-2017
			WO 2016063291 A1	28-04-2016
-----				
WO 2008028956	A1	13-03-2008	AT 511398 T	15-06-2011
			AU 2007293672 A1	13-03-2008
			AU 2007293673 A1	13-03-2008
			BR PI0716518 A2	08-10-2013
			BR PI0716519 A2	08-10-2013
			CA 2662051 A1	13-03-2008
			CA 2662064 A1	13-03-2008
			CN 103357003 A	23-10-2013
			CN 103585624 A	19-02-2014
			CO 6160334 A2	20-05-2010
			CO 6160335 A2	20-05-2010
			CR 10669 A	28-04-2009
			CR 10672 A	29-04-2009
			CY 1111680 T1	07-10-2015
			CY 1113419 T1	22-06-2016
			DK 2066344 T3	05-09-2011
			DK 2097102 T3	30-07-2012
			EA 200900288 A1	28-08-2009
			EA 200900289 A1	28-08-2009
			EP 2066344 A1	10-06-2009
			EP 2097102 A2	09-09-2009
			EP 2491947 A2	29-08-2012
			ES 2387582 T3	26-09-2012
			HK 1129563 A1	16-09-2011
			HR P20110431 T1	31-07-2011
			HR P20120557 T1	31-07-2012
			IL 197272 A	31-03-2016
			IL 197310 A	30-04-2012
			JP 5814507 B2	17-11-2015
			JP 2010502678 A	28-01-2010
			JP 2010502679 A	28-01-2010
			JP 2013256505 A	26-12-2013
			JP 2015028041 A	12-02-2015
JP 2016020361 A	04-02-2016			
KR 20090057423 A	05-06-2009			
KR 20090058552 A	09-06-2009			
MA 30715 B1	01-09-2009			
MA 30716 B1	01-09-2009			
NZ 575272 A	24-02-2012			

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2017/055100

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		NZ 575273 A	24-02-2012
		PT 2066344 E	05-07-2011
		PT 2097102 E	03-08-2012
		SI 2066344 T1	30-09-2011
		SI 2097102 T1	28-09-2012
		US 2010034850 A1	11-02-2010
		US 2010040647 A1	18-02-2010
		US 2015273047 A1	01-10-2015
		WO 2008028956 A1	13-03-2008
		WO 2008028957 A2	13-03-2008
<hr/>			